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AIMS AND OBJECTIVES 
 
AIM 
To study the level of anxiety in breast cancer patients receiving loco-regional radiation 
therapy and  to study its correlation with inter fraction variations observed during 
delivery of treatment. 
 
OBJECTIVES 
Primary: 
 To assess the level of anxiety of breast cancer patients during planning and 
treatment of radiation therapy. 
Secondary: 
 To measure the inter fraction variations during the course of  radiation therapy. 
 To correlate the anxiety levels with inter fraction variations recorded during the 
treatment. 
 To determine the need of counseling for anxious patients to reduce the inter 
fraction variations. 
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INTRODUCTION 
 
Breast cancer is the most frequent cancer among women according to the GLOBOCON 
2012 report. In India, breast cancer is the most common cancer contributing to 27% of all 
new cancers in women.  
Breast cancer requires multi-modality treatment including surgery, chemotherapy, 
radiation therapy and hormonal therapy. Many patients undergo radiation therapy as part 
of their treatment for breast cancer and the number is rising with increase in breast 
conservation surgeries. Various studies have looked into the psychological distress of 
patients undergoing radiation therapy. Studies have shown that the patients experience 
anxiety particularly prior to planning and at the start of radiotherapy treatment, likely due 
to the fear of unknown. This study aimed to estimate the level of anxiety of non 
metastatic breast cancer patients undergoing radiation therapy using the Beck anxiety 
inventory. The questionnaire was administered at the time of simulation, on the first three 
days of treatment and weekly once.  
Radiation therapy treatment consists of continuous treatment of five days a week for 3-5 
weeks. It involves radiation of the chest wall or whole breast with or without regional 
nodal irradiation. Tangential fields have been used conventionally to ensure minimum 
dose to the underlying normal tissue including the lung and heart. 3DCRT and IMRT has 
made it possible to achieve better dose distribution with high dose to the target and 
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sparing of the surrounding normal structures. However, with these conformal techniques,  
it is important to ensure accurate delivery of beams as per the treatment plan. Studies 
have shown there are daily variations which contribute to changes in irradiated volumes 
during treatment. On board electronic images are taken for verification of position and 
treatment volume. We can measure the inter-fraction variations by comparing the on 
board images with reference images and this helps to decide the appropriate setup margin 
for our planning. 
For treatment of breast cancer patients, other than setup uncertainties, organ motion due 
to breathing need to be taken into account during treatment planning and delivery. It was 
hypothesized that the change in breathing pattern may be correlated with the level of 
anxiety and altered breathing pattern during treatment would affect our planned treatment 
volumes. This study was a step to understand that whether anxiety causes a significant 
change in breathing pattern and hence significant increase in inter fraction variations. 
A positive correlation of anxiety with inter-fraction variability may provide a new insight 
into the need for improving communication with patients regarding the radiation therapy 
to alleviate their symptoms of anxiety. 
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REVIEW OF LITERATURE 
 
3.1 INCIDENCE - GLOBAL AND INDIAN EPDEMIOLOGY  
Breast cancer is the most common malignancy diagnosed in females throughout the 
world. According to WHO GLOBOCON 2012 report, breast cancer is the second most 
common cancer in the world and the most common cancer among women. An 
estimated 1.67 million new cases were diagnosed in 2012 (i.e. 25% of all diagnosed 
cancers). It is the most common cancer in women both in the developed and less 
developed regions of the world. Breast cancer is the fifth most common cause of 
cancer death overall. It is however the most common cause of cancer related death in 
women in less developed regions and second most common cause of cancer related 
death in the developed regions, first being lung cancer. 
In India, as per WHO GLOBOCON report 2012, number of new cases of breast cancer 
diagnosed in 2012 was 1,45,000 and number of deaths related to breast cancer was 
70,000. Based on review of population based cancer registry in India 2009-2011 data 
and Hospital based cancer registry 2007-2011, breast cancer accounts for 25% to 32% 
of all female cancers. Therefore, one fourth of all female cancer cases can be attributed 
to breast cancer.(1) 
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Figure 1.  GLOBOCON 2012 - Incidence and Mortality in India for both sexes 
 
Figure 2. GLOBOCON 2012 - Incidence and Mortality in India for women 
GLOBOCON 2012 - India (females) 
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The mortality from breast cancer is showing a declining trend as a result of earlier 
diagnosis through screening, improved surgical and radiotherapy techniques and more 
adjuvant therapies. Mortality rates are higher in younger women i.e. less than 35 years 
and very old i.e. more than 75 years. This is because young females have a more 
aggressive tumor and for very old women, aggressive treatment may not be feasible or 
there other co-morbidities may cause death. 
 
3.2 ETIOLOGY OF BREAST CANCERS 
Breast cancer is a heterogeneous disease caused by progressive accumulation of 
genetic aberrations, including point mutations, deletions, chromosomal amplifications, 
rearrangements, translocations, and duplications (2,3). Germ line mutations account for 
only about 10% of all breast cancers, while the vast majority of breast cancers appear 
to occur sporadically and are attributed to somatic genetic alterations. 
Breast cancer has many etiological factors including genetic and family history, 
estrogen exposure (based on menarche and menopause age, use of estrogen containing 
medictaions like oral contraceptive pills etc, nulliparity and lack of breast-feeding. It is 
also associated with history of certain breast conditions like papilloma or prior history 
of radiation therapy to the chest region (4). 
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3.3 ANATOMY OF BREAST (5) 
 
The female breast lies on the anterior chest wall superficial to the pectoralis major 
muscle. It extends from the midline to near the mid axillary line and cranial caudally 
from the second rib to the sixth rib. The upper-outer quadrant of the breast that extends 
into the region of the low axilla is frequently referred to as the axillary tail of Spence. 
This area contains a greater percentage of total breast tissue compared with the other 
quadrants, and, therefore, a greater percentage of breast cancers occur in this 
anatomical location. 
The breast is made up of mammary glands, fat tissue, blood vessels, nerves, and 
lymphatics. The surface of the breast is anchored to deeper tissue by fibrous septa 
called Cooper’s ligament, which run between the superficial fascia (attached to the 
skin) and the deep fascia (covers the pectoralis major and other muscles of the chest 
wall). The chest wall includes the ribs, intercostal muscles, and the serratus anterior 
muscle, but not the pectoral muscles. 
The predominant lymphatic drainage of the breast is to axillary lymph nodes, which is 
commonly described in three levels, based on the relation to the pectoralis minor 
muscle.  
 Level I axilla is caudal and lateral to the pectoralis minor muscle 
 Level II is beneath the pectoralis minor muscle,  
 Level III (also known as the infraclavicular region) is cranial and medial to the 
pectoralis minor muscle.  
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The axillary lymph nodes continue underneath the clavicle to become the 
supraclavicular lymph nodes, which can be involved in locally advanced breast 
cancers. Lymphatics can also drain directly into the internal mammary lymph node 
chain (IMC), which are intrathoracic structures located in the parasternal space. When 
breast cancer involves the IMC, the majority of patients will have disease that is 
limited to lymph nodes in the first three interspaces. Regardless of location in the 
breast, the axilla is the most common site of lymphatic involvement. However, breast 
cancers that develop in the medial, central, or lower breast more commonly drain to 
the IMC (in addition to the axilla) than those occurring in the lateral and upper 
quadrants. 
 
3.4 STAGING OF BREAST CANCER   
Breast cancer has been staged as per the AJCC 2010 (6) (Appendix 1) . Early breast 
cancer (EBC) comprises of Stages I, IIA, IIB and IIIA.  Locally advanced breast 
cancer (LABC) comprises of Stage IIIB onwards. 
 
3.5 HISTORICAL PERSPECTIVE 
Ancient Egyptians first noted the disease more than 3,500 years ago. Over the years, 
many theories came up to explain its occurrence and spread. It was understood that it 
spreads to lymph nodes and hence different surgical approaches aiming at removing 
the breast along with lymph glands were tried.  
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3.6 SURGERY 
Mastectomy, or removal of the entire breast tissue with the muscles of the chest wall 
including the pectoralis major muscle, is one of the surgical procedures used in breast 
cancer treatment. There are various types of mastectomy that have evolved over time. In 
the 1900s, Radical Mastectomy (Halsted mastectomy) was the standard of care for breast 
cancer (7). It reduced local recurrences, but caused significant side effects, functional and 
psychological morbidity and diminished quality of life. It resulted in gross deformity and 
problems of lymphedema and sensory abnormalities over the arm and chest. Hence over 
the next few years, more conservative surgeries evolved. 
The recent practice of surgery involves a more conservative approach which is known 
as the Modified Radical Mastectomy (MRM). It is a surgical procedure in which the 
entire breast is removed, including skin, areola, nipple, and most of the axillary lymph 
nodes, however, the pectoralis major muscle is spared. 
Long term follow up data of breast cancer patients treated by radical mastectomy 
showed that 30 year survival rate was about 38% (8).  It is rarely used now days. 
Modified radical mastectomy has been shown to have an equivalent survival outcome 
and lesser morbidity (9). Simple mastectomy is another new surgical technique that 
involves removal of entire breast while preserving the pectoral muscles and the 
axillary contents. With the emergence of data of use of sentinel node biopsy, simple 
mastectomy is being performed more frequently. Skin-sparing mastectomy (SSM) 
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involves preserving the natural breast skin envelope that provides the reconstructed 
breast with a more natural shape and contour and thus give a superior cosmetic 
result(10,11). It is considered to be an oncologically safe surgery. 
In cases of early breast cancer, nowadays a breast conservation approach is being used 
in which instead of the entire breast tissue, only the lump is removed with adequate 
margins. The EORTC 10801 trial on breast conservation surgery (BCS) versus MRM 
showed no significant difference in twenty year overall survival rate among women 
who underwent breast conservation surgery and radiotherapy and those who were 
treated with modified radical mastectomy, for early breast cancer (Stage I and II). 
Overall survival at 20 years was 44% in the BCS group and 39% in the MRM group. 
Time to distant metastasis also did not differ significantly between the two groups, 
however the study found that the 10-year locoregional recurrence of cancer was higher 
in the breast-conserving group than in the patients who underwent mastectomy (20% 
vs 12%, respectively) (12). 
There has been a paradigm shift in the understanding of the natural history of breast 
cancer from local disease theory to systemic disease theory. Surgical procedures have 
become less aggressive and less invasive and surgical treatment is just one part of the 
multidisciplinary treatment required in breast cancer (13). 
Today, the treatment of breast cancer is always a multimodality approach. Surgery 
forms the mainstay of management with radiation therapy and chemotherapy taking a 
major adjunct role (14). 
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3.7 CHEMOTHERAPY 
Role in adjuvant setting 
Chemotherapy was introduced in the fifth and sixth decades of the twentieth century 
and resulted in the development of curative therapeutic intervention in management of 
various cancers. In breast cancer, initially single-agent chemotherapy was used - 
cyclophosphamide, phenylalanine mustard, vincristine, vinblastine, methotrexate and 
5-fluorouracil. Bonadonna et al., in 1976 showed for the first time the efficacy of 
adding various chemotherapy agents together in the management of breast cancer.  
CMF (cyclophosphamide, methotrexate and fluorouracil) was used as an adjuvant 
treatment to radical mastectomy for breast cancer with lymph nodes positive disease 
and provided better local control of disease, better disease free and overall survival 
(15). Role of Adriamycin based chemotherapy in adjuvant setting was shown with 
further studies. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) studied 
recurrence and 15-year survival for different chemotherapy and hormonal therapy for 
early breast cancer. It showed that anthracycline based chemotherapy for 4–6 months 
(FAC or FEC) reduced annual breast cancer mortality rates by 38% in women less than 
50 years and by 20% in women aged 50–69 years. This was found to be more effective 
than the CMF regimen (16). This resulted in the change of chemotherapy regimens 
from CMF to anthracycline based  regimens which till date form the mainstay of 
chemotherapeutic management of breast cancer. 
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Role in neoadjuvant setting 
Chemotherapy is used in neoadjuvant setting in locally advanced breast cancer to 
downstage the disease. Response to chemotherapy in terms of complete pathological 
response (pCR) has been shown to be the strongest predictor of disease-free survival 
and overall survival (17). Cochrane meta-analysis in 2007 included 5500 women and 
showed neoadjuvant chemotherapy was associated with fewer adverse effects. It 
further confirmed that pathological complete response to neoadjuvant chemotherapy 
was associated with better survival than residual disease after chemotherapy (18). It 
also has a role in early breast cancer before considering breast conservation surgery. 
 
3.8 RADIATION THERAPY FOR BREAST CANCER 
 
Radiation Therapy forms an integral part in the management of breast cancer. It is 
beneficial in reducing the local recurrence and improving the overall survival after 
surgery in both early and locally advanced breast cancer patients. It is also beneficial in 
palliation of symptoms in cases of metastatic breast cancer. 
Indications for radiation therapy in breast cancer are; 
1. As an adjuvant treatment after breast conservation surgery in cases of early breast 
cancer 
2. As an adjuvant treatment after modified radical mastectomy in locally advanced breast 
cancer  
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3. For palliation of symptoms (bone pains, impending fracture, spinal cord compression 
and brain metastasis etc.) in cases of metastatic breast cancer 
In cases of early breast cancer, after a breast conservation surgery, the addition of 
adjuvant radiation therapy has shown to improve both local control and overall 
survival. The Early Breast cancer Trialists Collaborative Group (EBCTCG) conducted 
a meta-analysis from 17 randomized controlled trials which had 10871 patients of 
early breast cancer post breast conservation surgery. It showed a reduction in the 10-
year risk of any (ie, locoregional or distant) first recurrence from 35·0% to 19·3% 
(absolute reduction 15·7%) and reduced the 15-year risk of breast cancer related death 
from 25·2% to 21·4% (absolute reduction 3·8%) with the addition of adjuvant 
radiation therapy (19). They concluded that after breast-conserving surgery, 
radiotherapy to the conserved breast reduces the rate at which the disease recurs by 
half and reduces the breast cancer death rate by about a sixth. Based on the results of 
this meta-analysis and other randomized controlled trials, adjuvant radiation therapy is 
presently the standard of care after any breast conservation surgery. 
In cases of locally advanced breast cancers, or in patients who have undergone 
modified radical mastectomy, adjuvant radiation therapy has been found to be 
beneficial in cases where high risk factors are present. Randomized controlled trials 
from the Danish group and British Columbia studies first demonstrated the benefit of 
adjuvant post mastectomy radiation therapy in selected patients with high risk features 
(20,21). Later a meta-analysis published by the EBCTCG in 2014 showed that post 
mastectomy radiation therapy reduced both recurrence and breast cancer mortality in 
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the women with one to three positive lymph nodes. For women with axillary dissection 
and four or more positive nodes, radiotherapy reduced overall recurrence by 21% and 
breast cancer mortality by 13% (22).  
As per the ASTRO consensus guidelines, ASCO guidelines and American College of 
Radiology criteria (23–25), post mastectomy adjuvant radiation therapy is indicated in: 
1. Patients With Four or More Positive Axillary Lymph Nodes 
2. Patients with 1-3 positive axillary lymph nodes and presence of high risk features 
3. Patients With T3/T4, or Stage III disease 
4. Patients Undergoing Preoperative Systemic Therapy 
 
3.9 EVOLUTION OF RADIOTHERAPY 
 
Radiation therapy has evolved a lot in the past few decades. From the initial era of 2D 
conventional radiation therapy to 3D Conformal Radiation Therapy (3D CRT) and the 
present day era of Intensity Modulated Radiation Therapy (IMRT), Image Guided 
Radiation Therapy (IGRT), Volumetric Arc Therapy (VMAT), Tomotherapy and 
Intensity Modulated Proton Therapy (IMPT). This evolution has led to more precision 
based treatment with better dose distribution to the area of interest and less radiation 
dose delivery to the normal tissues. Hence, a higher therapeutic ratio can be achieved 
with better results.  
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3.10 TARGET VOLUMES FOR RADIATION THERAPY IN BREAST CANCER 
 
When radiation therapy is planned in any case of breast cancer, the area which is 
targeted depends upon the surgery which has been performed and the presence or 
absence of high risk factors for the inclusion of the nodal drainage areas. In a case of 
early breast cancer in which a conservative surgery has been performed, the target area 
comprises of the entire remaining breast tissue (excluding the chest wall) and the 
lumpectomy cavity (defined by the pre-surgical clinical and mammographic findings 
and surgical clips) which is given added dose of radiation therapy by a lumpectomy 
cavity boost. Inclusion of regional nodes depend on axillary approach during surgery 
(axillary clearnce versus sentinel lymph node biopsy), presence of other risk factors 
and administration of neoadjuvant chemotherapy.  
In cases where a more radical surgery has been performed and the entire breast tissue 
has already been removed, the target area comprises of the chest wall including the 
muscles and the ribs underneath. If high risk features are present which warrant the 
nodal areas also to be irradiated, then the axilla, supraclavicular area and the internal 
mammary areas are included in the target areas as required. 
 
3.11  ORGANS AT RISK 
The most critical organs in breast planning include lung, heart and contralateral breast 
tissue. Studies have shown that the risk of contralateral breast cancer after radiation 
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therapy for breast cancer is estimated to be a function of the radiation dose delivered to 
the contralateral breast. Most of the older studies showed no significant association 
with radiotherapy (26,27). However, in a relatively recent study (28), less than 3 
percent of second breast cancers were attributed to previous radiation treatment. The 
risk was higher among women who underwent irradiation at a relatively younger age 
(<45 years) (28). Thus, there is an emphasis on the need of reduction of dose to 
contralateral breast tissue. 
Volume of lung tissue irradiated during loco-regional irradiation of breast cancer 
patients correlates with the risk of lung toxicity. There is irreversible reduction in lung 
function parameters accompanied by radiological evidence of persistent lung injury 
suggestive of radiation pneumonitis (29,30). Hence, there is a need to minimize the 
lung dose during radiation therapy to prevent the long term complication of 
pneumotoxicity in breast cancer survivors.  
Morbidity due to irradiation of heart tissue, especially in  left sided breast cancer patients 
has also been reported in various studies(31,32).  Radiation related heart disease can be 
broadly classified into following conditions - pericarditis, pericardial fibrosis, valvular 
disease, diffuse myocardial fibrosis, and coronary artery disease. A meta-analyses by 
EBCTCG had shown that death due to heart disease was increased by 27% in breast 
cancer women who received RT after surgery compared with women who underwent 
surgery alone (33). The updated EBCTCG report related the cardiac mortality to 
estimated cardiac doses in 30,000 women followed up to 20 years and showed that there 
was radiation-related increase in cardiac events with larger mean cardiac doses. It 
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concluded that the risk of death from any heart disease increased by 3% per Gy of 
radiation therapy received to the heart (34).  With recent data, there is substantial 
evidence that has shown that mean heart doses of less than and equal to 20 Gy, and even 
less than 5 Gy can increase the risk of cardiac morbidities (35) 
 
Therefore, various beam modifying techniques are being used to reduce dose to these 
critical structures like use of half beam blocks, asymmetric jaws, heart blocks and 
wedges and some form of radiation beam fluence modulation 
 
3.12 CONFORMAL RADIATION TECHNIQUES 
The evolution in Radiation Therapy led to development of newer techniques of 
delivering radiation therapy which not only helped in achieving a good dose 
distribution in the target area, but also helped in reducing the doses to the adjacent 
critical normal structures.   
3D Conformal Radiation Therapy (3DCRT) 
3D CRT planning is done with the patients planning CT scan done in the position in 
which the everyday treatment will be delivered and then the target areas and the 
adjacent at risk organs are contoured cut by cut on the CT scan.  
In case of a breast cancer treatment, the beams in 3DCRT consist of two opposing 
tangential field portals which allow optimum coverage of the breast tissue and 
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minimizes the dose to the adjacent normal structures. Wedges (physical or dynamic) 
are added to these tangential beams to compensate for the changes in body contour and 
hence, this improves the dose uniformity in the desired target volume.  The obtained 
dosimetry is then confirmed based on the target coverage and the doses received by the 
organs at risk, which is plotted on a dose-volume histogram (DVH). ICRU 50 and 62 
are used for selecting an appropriate plan for the delivery of radiation therapy (36,37). 
Intensity Modulated Radiation Therapy (IMRT) 
In IMRT, the first steps of planning are similar to that followed in 3D CRT. The 
patient is positioned in the intended daily treatment position following which a 
planning CT scan is taken and a cut by cut contouring of the target areas and the 
organs at risk is done. After this, the dose constraints to the target area and the organs 
at risk is defined and an “Inverse Planning” technique is used for planning purpose.  
Multiple beams are used for inverse planning IMRT. The optimizer uses inverse 
planning objectives and anatomy contours to produce beamlets which give the desired 
dose fluence maps and dose distribution. ICRU Report 83 is used as a tool for plan 
evaluation in selecting the appropriate plan for IMRT technique (38). The American 
Society of Radiation Oncologists (ASTRO) has issued series of quality assurance and 
safety guidelines called as white papers to investigate and develop focused quality 
assurance methods for radiation therapy treatment. These white papers consolidate the 
abundant available knowledge to focus on preventing failures and complications (39). 
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IMRT has superior dosimetric advantages over 3-dimensional conformal radiotherapy 
(3DCRT) treatments. By using an inverse planning technique with predefined dose 
constraints and optimization, it improves conformity of the target dose facilitating 
escalation of dose that can  improve local control. It also reduces irradiation of nearby 
normal tissue which minimizes the degree of morbidity associated with the treatment 
(40). However, as IMRT used more number of radiation beams for delivering the 
radiation therapy, the low dose radiation area is increased in IMRT when compared to 
the conventional means of delivering radiation therapy.  
Harsolia et al. compared the acute and chronic toxicity of whole breast irradiation with 
IMRT versus conventional radiation treatment. They found that use of IMRT resulted 
in a significant decrease in acute dermatitis, edema and hyperpigmentation and also 
reduced the development of chronic breast edema(41).  
Field in field technique (FIF) 
Field in Field (FIF) technique is a newer modality of delivering IMRT for breast 
cancer. It is also referred to as “Forward Planning” IMRT. In this field in field 
technique, an open beam  is first planned and evaluated without any wedges, looking at 
the hot regions over critical structures. After this, subfields per gantry angle are 
planned in which MLCs can be moved manually to cover the hot regions. Also the 
monitor unit change iteration in these sub fields is done till an optimal dose coverage is 
achieved. Usually, a lung block field and three additional subfields per gantry angle are 
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used.  The open beam contributes about 80% of the delivered dose while the additional 
subfields contribute the remaining 20%. 
Several studies have shown Field in Field IMRT facilitates a better control of dose 
homogeneity and reduces hot regions as well as cold regions (42–47). Woo-Lee et al 
showed that there was an improved performance using the field in field technique 
compared with the conventional wedge and dynamic wedge system in terms of 
improved PTV conformity, while protecting the normal structures (48). Another study 
showed that with FIF technique, the heart volumes receiving 2 Gy, 30 Gy and 40 Gy 
were significantly reduced. Also, the ipsilateral lung volumes getting irradiated were 
significantly reduced.  
Other than these dosimetric advantages, FIF requires less planning time and is less 
skill dependent.  An inverse planning IMRT plan for breast consumes longer planning 
time, requires advanced planner skills and need for more MUs (49). Field in field 
technique being a simple and more efficient form is widely preferred in many centers 
for administering tangential radiotherapy to whole breast or chest wall.  
 
3.13 BREATHING PATTERN  
 
Normal respiration is an automatic, effortless inspiratory expansion and expiratory 
contraction of the chest. It has a relatively constant rate and inspiratory volume, both of 
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which together form the normal respiratory rhythm.  Breathing pattern characteristics 
include  
1. Posture - upright, supine, prone, lateral decubitus 
2. Breathing type - chest or abdominal 
3. Depth of respiration - shallow, normal, deep 
 
Figure 3. Normal breathing curve 
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Figure 4. Chest wall movements in normal breathing. 
 
Accurate control of breathing is under the central respiratory pacemaker which is 
located within the brainstem. This medullary respiratory center receives three kinds of 
feedback which alters its output and leads to changes in the number of breaths per 
minute and the volume of  each inspiration (50). One of the feedback input comes from 
the higher cortical centers. It includes the state of being awake which is associated with 
significant neural inputs to the respiratory center and when an individual falls asleep, 
this cortical input decreases thus altering the respiratory center output. The change in 
output from the respiratory center lead to alteration of the rate and tidal volume which 
affects the chest cage contraction and expansion. The higher center input can be 
increased with anxiety which may lead to hyperventilation. 
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3.14 DOSIMETRIC IMPACT OF RESPIRATORY MOTION AND DAILY 
SETUP ERROR 
 
The planned dose on planning CT scans differs from the actual patient dose during 
treatment due to respiratory motion and daily setup errors. Prabhakar et al. have 
reported the dosimetric impact of setup error and showed that isocentric shifts along a 
particular direction has a significant effect on the dose to PTV and critical structures. 
They concluded that the isocentre shifts should be checked prior to treatment and  the 
setup error in the isocenter should be kept strictly below 3mm (51).   
As per a study conducted by Furuya et al. (52), with FIF technique, significant 
differences in the mean dose and dose homogeneity index were noted even with a 0.5-
cm isocenter shift. Volume received 20 Gy radiation (V20) of the entire lung showed a 
change of 4% from the original plan if there was a shift in the isocenter in the antero-
posterior (AP) direction. They concluded that the FIF irradiation technique for breast 
cancer radiotherapy, was more sensitive to respiratory motion and setup error than the 
conventional techniques. However, they also found that the dosimetric impacts of this 
during the entire course of treatment was relatively small and might be clinically 
acceptable. 
Another study from Chicago by J. Cao et al. showed that for patients who had a large 
respiratory motion of  >0.6 cm (measured in their study with the marker movement) , 
the difference in coverage of Volume receiving 100% dose (V100) for the target 
volume was >10% and upto 18% (53). 
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However, a study by Robert Frazier on early-stage breast cancer patients who received 
whole breast irradiation had shown that the dose delivery to breast using step and shoot 
IMRT technique was relatively insensitive to the effects of breast movement due to 
normal breathing (54). 
During a phase of normal respiration, the lung volume changes by around 20%  (3.3 liters 
to 4.1 liters on average) (55). At end of deep inhalation, the increase in the lung volume is 
approximately three to four times that of normal breathing. The AAPM task report 76 on 
management of respiratory motion during delivery of radiation therapy, (56) has 
recommended that if the magnitude of the motion observed in any direction during 
treatment is greater than 5 mm or if there is chance of significant normal tissue sparing,  
dosimetric effect of motion should be considered and a respiratory management 
technique should be used.  
 
3.15 REDUCING EFFECT OF BREATHING ON RADIATION THERAPY 
 
Considering the impact of breathing pattern on homogeneity of radiation dose 
delivered to target volume and nearby critical structures, various methods have been 
described and under evolution for controlling the effect of breathing and respiratory 
motion during radiation therapy. These techniques may work by reducing the effect of 
respiration on treatment planning and delivery or by reducing the effect of inter 
fraction motion by daily or continuous verification of patient and simultaneous online 
correction of errors prior to treatment. 
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There are four main strategies which are commonly used to reduce the effects of 
respiratory motion (57) :  
1. Integrating respiratory movements into treatment planning 
2. Breath-hold techniques 
3. Respiratory gating techniques 
4. Tracking techniques.  
 
Integrating respiratory movements into planning (Motion encompassing 
techniques) 
In this technique of management of respiratory motion, the range of motion of the 
target and other structures due to breathing is estimated and their mean position is 
calculated. It can be based either on measurements done in a representative sample of 
general population, or measurements done directly on the patient before planning and 
delivering radiation therapy. The imaging which can be used for determining the 
desired range of respiratory motion are slow CT scans, inhale and exhale breath hold 
CT scan or 4D CT scan (58) . 
The measured amplitude is then added as a geometrical margin to get the internal 
target volume (ITV) which is then used in place of the Clinical Target Volume (CTV) 
for radiation therapy planning. The drawback of this technique is that it would result in 
larger irradiated volumes thus increasing the chances of increased dose delivered to the 
normal tissues. 
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Respiratory Gating 
It denotes the delivery of radiation during a specific phase of the respiratory cycle, 
often referred to as ‘Gate’. The patient's respiratory cycle is monitored using either 
external or internal signals like the infrared camera or fiducial markers and radiation 
delivery is allowed only during certain time intervals that is synchronous with the 
patient's respiratory cycle. This is particularly useful in reducing the effect of 
respiratory motion during the radiation therapy delivery (intra-fraction motion) 
(59,60). The Varian Real-time Position Management (RPM) system is the only 
commercially available software used for respiratory gated therapy. 
Breath holding techniques 
There are three types of breath hold methods which are used for managing the 
respiratory motion during delivery of radiation therapy.  
1. Active Breathing Control (ABC) 
2. Self-held breath-hold and Self-held breath-hold using an External Marker  
3. Deep inspirational breath hold (DIBH).  
In active techniques, an ABC apparatus which has a valve is used to temporarily block 
airflow of the patient and the radiation therapy is delivered in that particular time, thus 
nullifying the effect of respiratory motion.  
Active breathing control (ABC) has been tried by various institutions. Its feasibility 
and practicality in terms of patient's tolerance is under investigation. With ABC, the 
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patient's breathing is temporarily immobilized and treatment planning and delivery is 
performed at identical ABC condition. This allows for safe margin reduction for target 
volumes with minimal margin for breathing motion (61). The results have been 
encouraging, ABC may possibly provide a simple mean of minimizing breathing 
motion in thoracic irradiation.  
The self-holding techniques are voluntarily breath-hold techniques also called as 
passive techniques. 
In DIBH which is a controlled breathing technique, patient performs a supervised 
breath hold during the treatment. It thus reduces the respiratory motion (60).  It 
requires more patient effort than respiratory gating. Korreman et al. studied the 
cardiopulmonary dose sparing effect of respiratory gating (named as  breathing 
adapted radiotherapy - BART) using free breathing gating and compared this with 
voluntary breath-hold techniques - deep inspiration breath-hold (DIBH) and end-
expiration breath-hold (EBH). The Varian RPM was used to monitor the respiratory 
movements and for gating the scanner. They found that there is a significant chest wall 
motion during treatment. The mean anterior-posterior chest wall excursion during free 
breathing was 2.5 mm whereas for DIBH and EBH, it was 4.1 and 2.6 mm 
respectively. Thus, both respiratory gating or DIBH technique, were comparable in 
their results and were found to substantially reduce the cardiac dose and lung dose in 
adjuvant radiotherapy after breast-conserving surgery for breast cancer patients (62). 
 
Tracking techniques  
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Tumour tracking consists of two major aspects - a real-time localization of the 
constantly moving tumor and real-time beam adaptation to this moving tumor. Thus, it 
dynamically accommodates with the respiratory motion of the patient by shifting or 
sweeping the beam in space (63). This technique is less practiced due to limited 
experience, increased costs for tracking devices and limited technical expertise. 
 
3.16 ANXIETY  
 
Anxiety is defined as the apprehensive anticipation of future danger or misfortune 
accompanied by feelings of dysphoria or somatic symptoms of tension (64). Pathological 
anxiety is defined under World Health Organization’s International Classification of 
Disorders (ICD–10) (65) and the American Psychiatric Association’s Diagnostic and 
Statistical Manual (DSM-IV) (64). It requires symptoms out of proportion to the level of 
threat which persists or deteriorates with no intervention and the intensity of symptoms is 
disproportionate to the intensity of the threat. There is disruption of the usual functioning 
of the patients. 
In the standardized diagnostic systems, four main types of anxiety disorders are 
defined. 
1. Anxious adjustment disorder - represents quantitatively excessive response to a 
stressful event 
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2. Generalized anxiety disorder - can be due to severe negative life-event and requires 
more symptoms  
3. Anxiety in panic disorder - builds up in a rapid crescendo and has a rapid exit with exit 
from the situation in which it occurs 
4. Phobic anxiety - only occurs in specific situations in the presence of provoking stimuli. 
In this type of anxiety, anticipatory avoidance is possible. 
 
The pathological anxiety criteria is difficult to apply to cancer patients as they have a 
constant threat of loss, death, body functions, roles, body image, etc (66). The natural 
history of anxiety in oncology is also uncertain. 
 
3.17 ANXIETY IN CANCER PATIENTS 
 
Anxiety in cancer patients can be categorized into three groups (67):  
1. Reactive anxiety - It is the most common form of anxiety in cancer patients. It 
corresponds to the adjustment disorder. However, it varies in duration, intensity and 
functional impairment. It can be due to waiting for starting of new treatment, uncertainty 
of future and treatment effectiveness. 
2. Pre-existing anxiety disorders - Patient may have underlying panic disorders, phobias, 
generalized anxiety disorders or post-traumatic stress disorder. These can be 
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differentiated from anxiety due to cancer in terms of duration and would usually be 
diagnosed preceding to the diagnosis of cancer.  
Phobias like fear of witnessing blood or tissue injury or claustrophobia may interfere with 
the administration of cancer treatment and may lead to anticipatory anxiety. 
3. Anxiety related to medical illness - This can be due to underlying causes like 
uncontrolled pain, metabolic causes, and medications like steroids, withdrawal states 
from alcohol, narcotic analgesics or due to a hormone secreting tumors.  
Anxiety is a major symptom seen in cancer patients. It produces a number of symptoms 
and signs like symptoms due to autonomic over-activity which include palpitation and 
sweating. Behaviors such as restlessness and changes in thinking like apprehension, 
worry and poor concentration. Physical symptoms may also be seen such as muscle 
tension or fatigue. 
Anticipatory anxiety has been defined as the appearance of anxious symptoms and 
feelings in days or hours before a feared event, and a rapid decline in these symptoms 
after the event has occurred (68). It leads to autonomic arousal. It can be experienced by a 
person with or without an underlying anxiety disorder. It is thus usually a normal reaction 
that may be experienced by any person, however, it may lead to emotional distress or 
may be a sign of clinically relevant anxiety (69).  Anxiety has been described to be either 
a relatively stable personality characteristic i.e. trait, or anxiety generated as a result of 
the situation or state. Some patients have high levels of trait anxiety which will be 
noticeable throughout the disease course. 
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Stark et al. reported a prevalence of anxiety in cancer patients in the United Kingdom to 
be 10-30% (70). Jenkins et al. reported that in a general population, younger women were 
more prone to anxiety(71). However, Noyes et al. (72)  showed that in cancer patients- 
age, gender, social class and education level were not consistently associated with 
anxiety. 
A study by Andersen and Tewifik (73) which looked into the psychological responses of 
patients receiving external radiation therapy found that there was a significant change in 
state anxiety from pre-treatment to post-treatment. However, the trait anxiety scores 
showed no significant difference across the treatment course. These findings were 
consistent with the Janis model, which showed that in case of a threatening situation, the 
level of fear and anxiety can potentially determine the adequacy of adaptation of a person 
(74). 
 
3.18  ANXIETY IN BREAST CANCER PATIENTS 
 
Amongst the breast cancer patients, there is a high proportion of patients who have 
anxiety disorders. A study from Thailand which looked into anxiety and depression in 
300 women diagnosed with breast cancer showed that the prevalence of anxiety disorder 
was 16 % while that of anxiety symptoms was 19%. They suggested that being alert on 
emotional reactions and potential psychiatric disorders among patients is essential during 
treatment (75).   
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A systematic review (76) of studies published between 1990-2010 looked into anxiety  
levels in breast cancer patients during treatment. It included stage 0 to stage IIIA patients 
who had had undergone chemotherapy, radiotherapy and surgery. Anxiety level in 
women was upto 91% before the first chemotherapy infusion and reduced in subsequent 
infusions.  Different radiotherapy regimen were compared and it was found that no 
significant difference existed in the level of anxiety between patients who received the 
short regimen and long regimen treatment. This study also concluded a higher level of 
anxiety among women who underwent mastectomy compared to those women who 
underwent breast conservation surgery. 
Various studies have reported anxiety in cancer patients who receive radiotherapy for 
different sites of malignancy (77). Lewis et al. reported 5-16% clinically relevant anxiety 
in patients during radiotherapy based on visual analogue scale scoring (68). They also 
found significant differences in pre-treatment and post-treatment scores at the time of 
simulation and first session of RT.  Thus, they concluded that before starting treatment 
and during treatment, it is important to check patient’s understanding and identify those 
patients who would require appropriate support throughout the treatment. They further 
extended their study assessing the communication provided to the patients during RT 
simulation. Clinically relevant anxiety during first session of RT was related to less 
efficient communication with the radiotherapy team, the perception of lower support 
from the radiotherapy team and lower knowledge of side effects (78). 
A study by Bidstrup et al. looked into the trajectory of anxiety and other distress in 
breast cancer patients and showed that women moved from severe anxiety at diagnosis 
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to a moderate level after four and eight months. Association on anxiety with 
radiotherapy showed an odds ratio of 1.16 [CI 0.57–2.36]. A younger age, poor family 
support and shorter education were associated with more risk of chronic distress. 
Patients who received chemotherapy but not radiotherapy showed severe psychological 
symptoms eight months after diagnosis. There was no subgroup of women with 
chronically severe anxiety, only one subgroup showed chronically severe distress in 
8% women (79). 
 
3.19 REASONS FOR ANXIETY 
 
The anxiety can be due to the diagnosis of the disease, the treatment or due to the fear of 
uncertainty. Diagnosis of cancer generates various forms of psychosocial distress among 
patients and anxiety forms one of this type of distress.  
The prolonged cancer treatment further adds to the anxiety as there can be positive or 
negative implications of treatment and unpleasantness of side effects. The patients feel a 
threat from these processes while having a hope of relief from the illness. 
The women who are advised radiotherapy know little about this treatment and 
experience treatment related anxiety. Studies have shown that their main concern is 
about the impact of treatment on their health in the future. Thus, there are high 
information needs among patients prior to treatment planning and commencing 
treatment and their anxiety persists until after the commencement of the treatment (80). 
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Substantial correlation has been found between anxiety and poor communication with 
the medical team (81). 
 
3.20 MANAGEMENT OF CANCER ASSOCIATED ANXIETY 
 
There is a need of an effective communication with patients to help reduce the cancer 
related anxiety. It is important for the health professionals to discuss about 
radiotherapy with patients and this opportunity should be taken up at the planning 
appointment, prior to the starting of treatment. There is a need to assess patients' 
understanding and concerns about radiotherapy and listen to their fears and provide 
reassurance about radiotherapy and the management of its side effects (82). 
Workshops encouraging open questioning with patients and discussions on psychological 
issues and empathy while discouraging ‘advice mode’ were shown to achieve enduring 
change and more awareness on patients' psychological distress (83). 
 
3.21 SCALES FOR MEASURING ANXIETY 
 
Various scales have been describe to assess the level of anxiety.  
 Beck anxiety inventory (BAI) 
 Hospital anxiety and depression scale (HADS)  :  14-item scale measuring symptoms of 
clinical depression and anxiety (84) 
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 Brief symptom inventory (BSI) : 18-item scale measuring somatization, depression, 
anxiety and general distress (85) 
  Profile of mood states (POMS) :  65-item scale measuring six mood states: anxiety, 
depression, fatigue, confusion, anger, vigor (86) 
 State-trait anxiety inventory (STAI): 40-item measure that indicates the intensity of 
feelings of anxiety. It differentiates between state anxiety (a temporary condition 
experienced in specific situations) and trait anxiety (a general tendency to perceive 
situations as threatening) (87) 
 Visual analogue scale 
 
3.22 BECKS ANXIETY INVENTORY 
 
The Becks Anxiety Inventory (BAI) was developed by Dr. Aaron T. Beck (88). It 
includes total of 21 items, each is rated on Likert scale from 0 (not at all) to 3 (severely) 
based on patient's response. The items on the BAI are simple descriptions of symptoms of 
anxiety in one of the four expressed aspects:  
 (1) Subjective component (e.g., "unable to relax") 
 (2) Neurophysiologic component (e.g., "numbness or tingling") 
 (3) Autonomic component (e.g., "feeling hot") 
 (4) Panic-related symptoms (e.g., "fear of losing control").  
 
As per the Beck anxiety inventory (BAI) usage guidelines, this questionnaire can be 
administered via self-report or via a trained administrator. It is simple and can be 
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completed in 5-10 minutes. The BAI items describe the subjective, somatic and panic 
related symptoms of anxiety but not of depression and hence it can fairly discriminate 
anxiety from depression. It has focus on many somatic symptoms of anxiety and assess 
symptoms like nervousness, inability to relax, dizziness etc. Compared to various other 
available scales, it obtains a purer measure of anxiety which is relatively independent of 
depression. 
The interpretation of the score is done as follows:  
Summing the scores for 21 items gives the total score, this may range from 0-63.  
   0–7    = Minimal anxiety 
  8–15   = Mild anxiety 
 16-25   = Moderate anxiety 
 26–63   = Severe anxiety 
Validity : Construct validity studies have shown a good convergence of the BAI with 
other anxiety scales like the HADS (r = 0.51), the STAI (r =0.47–0.58), and the 
anxiety scale of the Symptom Checklist-90 (r = 0.81)(89) . Also BAI has been assessed 
and found to be useful self-report scale in assessing anxiety symptomatology among 
the older adults (90).Netherlands Study of Depression and Anxiety (NESDA) had 
shown that BAI scores in patients with an underlying anxiety disorder or an underlying 
depressive disorder were significantly higher.  Thus it may be used as a severity 
indicator of anxiety in patients with different anxiety disorders(91). 
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Reliability : A meta-analysis was conducted by University of Nebraska–Lincoln for 
coefficient alpha and test-retest reliability estimates which showed that the diagnostic 
classification of participants and the within-study BAI score variability were well 
related to the magnitude of the reliability estimates (92). Internal consistency presented 
by cronbach's alpha of 0.94 was high with BAI. It also fared better than Trait Anxiety 
on tests of convergent and discriminant validity and it was found to be significantly 
less confounded with depression as measured by the Beck Depression Inventory. 
However, the scores for STAI  were highly confounded with depression (93). 
As the breast cancer patient undergoing various modalities of treatment suffer from 
distress both due to anxiety and depression, BAI was the preferred scoring used in our 
study taking into consideration the above factors. It is a brief, validated, easily 
administered and easily scored measure of anxiety. 
 
3.23    EFFECT OF ANXIETY ON BREATHING PATTERN 
Anxiety in breast cancer patients during radiation therapy may lead to changes in 
breathing pattern. The respiratory rate is noted by observing the frequency of the 
inspiratory phase and recording the number of breaths per minute. During normal 
breathing, the expansion of the chest cage which is dependent on the respiratory rate 
and depth of respiration should be the same for each cycle. In anxious patients, there is 
increase input from higher center to the respiratory pacemaker in the medulla which 
alters: 
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1. Number of breaths per minute i.e. the respiratory rate and 
2. Tidal volume i.e. the depth of respiration 
Thus, the inspiratory expansion of the chest cage varies. 
 
Figure 5. Change in breathing curve with hyperventilation 
 
 
Figure 6. Changes in breathing movement may occur during the course of 
treatment. 
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Minute ventilation is the amount of air that a person breaths per minute and is a 
product of the respiratory rate and tidal volume. An increase in the minute ventilation 
is seen in subjects with high anxiety. The increase in respiratory rate is more than tidal 
volume in anxious patients resulting in a positive correlation between the anxiety score 
and respiratory rate (94). Anxiety creates a situation of hyperventilation in which there 
is an increase in the rate of respiration and the depth of respiration becomes shallow. 
This means that the chest wall expands less than the normal expansion during a full 
inspiration. This variation in the chest wall movement leads to inter fraction variations 
during the delivery of radiation therapy. 
The radiation therapy planning, defining target volumes and measurement of irradiated 
lung tissue assumes a normal breathing pattern with constant chest expansion in each 
cycle. In anxious patients with the above changes, the irradiated target volume and 
lung volumes would vary and they can lead to a variation from the originally planned 
radiation therapy plan 
  
 
3.24 INTERFRACTION AND INTRAFRACTION VARIATIONS DURING 
RADIATION THERAPY 
 
With the newer techniques in use like IMRT, FIF, VMAT etc., highly conformal dose 
distribution can be achieved around the planning target volume (PTV) with reduction 
in the radiation dose to the normal tissues. There is increased accuracy of radiation 
delivery which is based on the initial planning CT scan done for the patient and any 
deviation in the anatomy of the patient from this CT scan can lead to wide variations in 
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the radiation therapy dosimetry. Thus, any amount of motion observed during these 
newer techniques is of greater consequence than in the traditional conventional plans. 
Immobilization is necessary to ensure reproducibility of position and accurate 
localization of the treatment volume.  
Inter-fraction variations 
Inter-fraction motion is the variation seen in position during different treatment 
fractions. It has both systematic and random components. Systematic error is the 
average variation in treatment position during the course of radiation therapy compared 
with the planning CT reference images which is constant. . It may be due to error in 
immobilization or positioning, error in target delineation, error in planning or error in 
reproduction of the initial planning position. Any mistake made at any of these levels 
can lead to a systematic error.  Random error is the variation in treatment position seen 
in daily fractions which is difficult to avoid and is taken care of by the margins given 
during the planning procedure  
Intra-fraction variations 
Intra-fraction motion is seen during delivery of a radiation treatment beam on a 
particular day. It is due to patient movement or internal organ motion while treatment 
is ongoing. It is a random error. 
Systematic error is more important for designating margins in radiotherapy treatment 
as a small error occurring repeatedly may have a more cumulative effect on dosimetry 
than a large error occurring once. Lawson et al. found the random errors were greater 
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than the systematic errors and position verification prior to treatment delivery with an 
on-board imaging (OBI) may help reduce the random component (95). 
 
3.25 METHODS OF RADIATION DELIVERY VERIFICATIONS 
 
Various on-board imaging (OBI) techniques are available to measure the variation with 
reference to the digitally reconstructed images of the planning CT scan. These include  
 Port films 
 Electronic portal imaging device (EPID) 
 Cone beam computed tomography (CBCT) 
These modalities allow to verify the treatment position, minimize the effect of motion 
by analyzing the images and simultaneous correction of the errors prior to treatment. 
Portal imaging 
It involves the acquisition of images with radiotherapy beam which are then used to 
verify the treatment position prior to the treatment delivery. Geometrical verification 
requires the portal image to be registered with a reference image obtained at the time 
planning (96). 
 
It was initially film based with subsequent development into film-less electronic portal 
imaging devices (EPID). Megavoltage (MV) radiation was used to acquire these 
images which were then compared to the kV images of a simulator. Nowadays, most 
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linear accelerators have kilovoltage (kV) imaging for acquisition of these images. This 
provides a better image contrast and quality than MV imaging and reduces the 
radiation dose due to verification images.  
EPID 
It is a very useful tool in measuring the inter-fraction variations during radiation 
therapy. Electronic images are taken which can be viewed instantaneously and 
matched to the planning digitally reconstructed radiographs (DRRs) before initiating 
the treatment. The measured deviation from the intended isocenter will thus give the 
magnitude of the error. Various studies have proven the advantage of kV imaging unit 
mounted on traditional LINAC for quantification of setup variability and its correction 
prior to treatment in comparison to the earlier mounted MV imaging (95,97). 
Orthogonal images can be acquired and isocenter shift can be measured by the use of 
on-board imaging techniques (95). Some studies have taken tangential field EPIDs to 
assess the inter-fraction variation. Acquisition of these images was found to be a quick 
and easy way to establish the amount of patient movement during breast radiotherapy.  
EPID can be used to measure variations from treatment to simulation (systematic 
error) and from treatment to treatment (random error).  
CONE BEAM CT  
It quantifies the inter-fraction motion in three dimensions. Daily cone-beam CT 
(CBCT) imaging can be used to measure the inter-fraction motion during breast IMRT. 
Studies have quantified the daily PTV volume variation to be upto 23%. This reveals 
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high inadequacies of patient positioning and need of stringent verification during 
IMRT delivery (98). 
 
A systematic review (99) to evaluate the inter-fraction and intra-fraction variation 
during radiotherapy to the whole breast showed inter-fraction variation was larger but 
on an average within a tolerance of 5mm. Thus, for breast cancers a PTV margin of 
5mm may be considered adequate. However, there were large maximum variation 
observed for some patients which define the need of daily imaging for position 
verification, more so for highly conformal treatment techniques.  
 
3.26 MEASUREMENTS TO DETERMINE MAGNITUDE OF ERRORS 
 
Central lung distance (CLD) 
It is the perpendicular distance from the posterior tangential field edge to the posterior 
part of the anterior chest wall at the center of the field. Bornstein et al. (100) conducted 
a study to determine the relation between CLD and percentage of irradiated ipsilateral 
lung volume in the tangential fields. It showed the following correlation between the 
two parameters. 
CLD                          Percentage of ipsilateral lung volume 
1.5cm                               6% 
2.5cm                              16% 
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3.5cm                              26% 
 
Thus, they concluded that the CLD measured at the time of simulation gives an 
estimate of the percentage of the lung volume irradiated and thus CLD should be kept 
to the minimum at the time of simulation. An increase in the CLD signifies an increase 
in the irradiated lung volume which in turn increases the incidence of radiation induced 
radiation pneumonitis. 
Central irradiated width (CIW) 
It is the distance between the posterior field border and the anterior breast outline at the 
level of central axis. 
Central beam edge to skin distance (CBESD) 
It is the distance from the anterior breast outline to the anterior field edge at the level 
of central axis. 
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Figure 7. Measurements taken to determine the inter-fraction error. 
 
Another method of measuring the magnitude of motion is by using the anatomical 
landmarks to match the images, following which it gives the computer calculated shift 
of the isocentre. It calculates the following parameters : 
 Anterior-posterior shift / Vertical shift 
 Medio-lateral shift  / Lateral shift 
 Cranio-caudal shift / Longitudinal shift 
 
 
CLD       : Central Lung Distance 
CIW       : Central irradiated width 
CBESD  : Central beam edge to skin 
  distance 
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MATERIALS AND METHODS 
 
Study Design 
A total of 27 patients with early-stage or locally advanced breast cancer who received 
whole breast or chest wall irradiation with or without regional nodal irradiation using 
the conformal technique were chosen for this study. 
Inclusion criteria: 
 Females more than >18 years 
 Diagnosed to have biopsy proven breast cancer 
 Patients who have undergone surgery for breast cancer (either lumpectomy 
or modified radical mastectomy) 
 Patients who require adjuvant radiation therapy for breast cancer 
 Patients willing for radiation therapy treatment with conformal techniques  
 Patients willing to sign the consent form and be a part of the study 
 
Exclusion criteria: 
 Patients with diagnosis of male breast cancer 
 Patients not willing for treatment with conformal techniques  
 Patients not willing to be a part of the study 
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RT planning 
All the patients included in the study underwent a planning CT scan under free-
breathing conditions in Biograph true point high definition CT scan (Siemens, 
Germany) with 5.0 mm slices to encompass the entire thorax. 
A breast board was used to immobilize patients in the supine position with arms above 
head. All patient underwent simulation for marking of three external fiducial markers 
in the simulator which were then tattooed. Radio-opaque markers were placed on these 
tattooed sites during the planning CT scan. Approximate field borders were also 
marked during the simulation. While taking the planning CT scan, the field borders 
and surgical scar site was marked using lead wires. 
 
Dose, target volume and critical structure delineation 
Two fractionation schemes were used for the treatment of the patients (administered 
five days a week): 
 Hypofractionation: 4005 cGy in 15 fractions, 2.67cGy per fraction over 3 
weeks                                                    
 Conventional fractionation: 5000 cGy in 25 fractions, 200 cGy per fraction 
over 5 weeks   
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The sites of radiation therapy were individualized based on the stage of breast cancer, 
neoadjuvant treatment received or not, receptor status and histopathological factors in 
the surgical specimen. The axilla was treated only if there was gross extranodal 
extension, inadequate axillary dissection or positive sentinel lymph node biopsy with 
no subsequent axillary dissection. Patients for whom axillary lymph node irradiation 
was planned, they were not considered for the hypofractionated regimen. 
CT image sets were imported to the Eclipse treatment planning system (Version 10.0) 
for contouring and treatment planning. The body, clinical target volume (CTV) and 
organs at risk (OAR) including lungs, heart, esophagus, contra lateral breast, spinal 
cord were contoured on each CT slice. RTOG breast contouring guidelines were used 
for contouring (Appendix II).  
Boost to lumpectomy cavity was planned for all patients who underwent breast 
conservation surgery. It was delineated based on the surgical clips and pre-operative 
clinical and radiological findings. Dose prescribed to the lumpectomy cavity was 10 Gy 
in 5 fractions (2 Gy per fraction for 5 days).  Gel bolus was used for all patients during 
the course of treatment and they were assessed weekly once while on RT for any 
radiation induced dermatitis or other complications. 
 
Treatment planning 
Field in field (FIF) conformal technique with a single isocentre was used for all patients. 
The isocenter was set at the junction between the supraclavicular field and breast 
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tangential fields. All open tangential fields included a 2.0 cm flash beyond the patient 
skin surface to take into account the patient’s breathing movement and setup error. A 6 
MV photon beam was used for all tangential fields. 
 
 
Figure 8. Single isocentre technique with isocentre at the junction between the supraclavicular field 
and breast tangential fields. CT centers were tattooed on patients' body to help in setup during 
treatment.  
 
The breast has a complex external shape. It requires dynamic wedges to achieve a 
homogenous dose distribution. In the field in field (FIF) technique planned for our 
patients, firstly two main open photon tangents were set and dose distribution was 
calculated. For medial tangent, 7-8 subfields were created with MLC changes to 
remove the hot spots. Subfields in lateral tangent were used only in few patients to 
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achieve better dose homogeneity. The monitor unit (MU) weightage was subsequently 
adjusted for the main radiation field and sub-fields so that the dose distribution was 
uniform at all levels in the planned target volume as per the ICRU recommendation 
(95% to 107%).  The supraclavicular field was included in the medial tangent field and 
dose deficit to the region was calculated which was then prescribed with an additional 
direct anterior field. Bolus was added to the tangential fields. Anisotropic Analytical 
Algorithm (AAA) (Version. 10.0) with inhomogeneity correction was used to calculate 
the dose for each plan.  
A dose–volume histogram (DVH) analysis was performed for all generated plans. The 
dose indices used to evaluate the plan quality were as follows: 
Table 1. DVH constraints for PTV evaluation. 
  Conventional        Hypofractionated 
PTV Ideal V95> 95% 
At least 95% of PTV 
receives 47.5 Gy 
V95> 95% 
At least 95% of PTV 
receives 38 Gy 
 
Acceptable At least 90% of PTV 
receives 45 Gy 
At least 90% of PTV 
receives 36 Gy 
PTV Dmax Ideal Dmax < 115% 
Maximum dose does 
not exceed 57.5 Gy 
Dmax < 115% 
Maximum dose does 
not exceed 46 Gy 
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Acceptable Dmax < 120% 
Maximum dose does 
not exceed 60 Gy 
Dmax < 120% 
Maximum dose does 
not exceed 48 Gy 
Table 2. Dose constraints for organs at risk. Dose (C) - dose constraint for conventional 
fractionation. Dose (H) - dose constraint for hypofractionated RT. 
  Volume Dose 
(C)  
Dose 
(H) 
 
IPSILATERAL  
LUNG 
Ideal No more than 15% exceeds  20 Gy 16 Gy 
Acceptable No more than 20% exceeds   20 Gy 16 Gy 
Ideal No more than 35%  exceeds 10 Gy 8 Gy 
Acceptable No more than 40% exceeds 10 Gy 8 Gy 
Ideal No more than 50%  exceeds     5 Gy 4 Gy 
Acceptable No more than 55%  exceeds     5 Gy 4 Gy 
 
CONTRALETRAL 
LUNG 
Ideal No more than 10% exceeds 5 Gy 4 Gy 
Acceptable No more than 10% exceeds 5 Gy 4 Gy 
 
HEART 
Ideal No more than 5% for left-
sided and 0% for right-
sided exceeds 
  20 Gy 16 Gy 
Acceptable No more than 5% for left-
sided and 0% for right-
sided exceeds 
  25 Gy 20 Gy 
Ideal 
 
No more than 30% for left-
sided and no more than 
10% for right-sided exceeds 
10 Gy 8 Gy 
 
Acceptable No more than 35% for left-
sided and no more than 
15%  for right-sided 
10 Gy 8 Gy 
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exceeds 
Ideal  
 
Mean heart dose does not 
exceed 
400 cGy 
 
320 cGy 
 
Acceptable Mean dose does not exceed 500 cGy 400 cGy 
 
CONTRALTERAL 
BREAST 
Ideal Dmax does not exceed 310 cGy 240 cGy 
Acceptable Dmax does not exceed 496 cGy 384 cGy 
Ideal No more than 5% exceeds 186 cGy 144 cGy 
Acceptable No more than 5% exceeds 310cGy 240 cGy 
 
 
Measurement of Anxiety level 
All the patients who consented to be a part of the study underwent anxiety scoring 
using Beck Anxiety Inventory (BAI) at the following time during the course of 
planning and treatment of radiotherapy: 
1. Before the simulation 
2. Day 1, Day 2 and Day 3 of radiotherapy treatment 
3. Weekly once during the treatment 
The patients' anxiety scoring was taken 6-8 times based on the duration of their 
treatment which varied from 3-5 weeks. It was interpreted as follows: 
    0–7   =  Minimal anxiety 
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  8–15   =  Mild anxiety 
 16-25   =  Moderate anxiety 
 26–63   =  Severe anxiety 
 
 An attempt was made to find a correlation between the baseline anxiety 
level of the patients and other patient related parameters like age, occupation, type of 
surgery, duration of treatment.  
Digitally reconstructed images (DRR) 
From the planning CT scan, digitally reconstructed images (DRR) were obtained for 
antero-posterior and lateral setup (AP and Lateral DRR).  Similarly digitally 
reconstructed images were obtained for main tangential fields for the medial and 
lateral gantry angles. 
Measurement of Inter- fraction variation  
On board imaging (OBI) was used for all patients on specified days prior to the 
delivery of radiation therapy. It can be remotely extended or retracted by the treating 
radiographer using the control console station. There is a dedicated OBI console and a 
software system for the same.   
Four electronic portal images (EPI) were taken for each patient on any particular day: 
 Anterio-posterior (AP) 
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 Lateral  
 Medial field EPID 
 Lateral field EPID 
 
Figure 9. Planning System showing beams eye view of a tangential field for a patient. 
After positioning the patient on the breast board in the treatment position, first 2 
orthogonal EPIs were taken. DRRs obtained from the planning CT scan were used as 
reference images for position verification of the patient. The treatment console system 
allows matching of the images to be performed either manually or automatically. The 
OBI was first automatically superimposed with the reference image and then this was 
verified manually and adjusted as per required to get the positioning errors. As the PTV 
margin used for our plans was 5mm, any shift within 5 mm from the initial planning 
position was considered to be acceptable,  while a shift of more than 5mm was corrected 
before delivering the treatment.  After the above positional verification, for the purpose 
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of this study, medial and lateral tangential field EPIs were taken and the positional 
differences were recorded. The patient was subsequently treated.  
The dose delivered during an EPID is 1cGy and as we have taken two extra field EPIs per 
day for the patients for 5 to 7 days depending on the duration of treatment, it can be 
assumed that there was an exposure of extra 10cGy to 14cGy of radiation due to these 
extra images. This is a very small dose and it was delivered to the treatment field with no 
extra radiation dose delivered to the normal surrounding tissues. 
As a routine protocol for all conformal treatments at our institute, image verification is 
done is done on first three days of treatment and then subsequently weekly once. In this 
study, same protocol of image verification was used and along with the AP and lateral 
images, medial and lateral field EPIs were also taken during these sessions.  
 
The following shifts were noted from the AP and lateral images:  
1. Vertical shift 
2. Lateral shift 
3. Longitudinal shift 
The following measurements were done on the medial and lateral tangential field 
images: 
1. Central lung distance (CLD) - perpendicular distance from the posterior tangential 
field edge to the posterior part of the anterior chest wall at the center of the field 
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2. Central irradiated width (CIW) - perpendicular distance between the posterior field 
border and the anterior breast outline at the centre of the field 
3. Central beam edge to skin distance (CBESD) - perpendicular distance from the 
anterior breast outline to the anterior field edge at the center of the field. 
These shifts were recorded from Day1- Day 3 of radiotherapy and then subsequently 
weekly once.  
 
Figure 10. CLD measurements on a tangential field electronic portal image 
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Figure 11. CIW and CBESD measurements on a tangential field electronic portal image. 
 
Figure 2 and 3 show tangential field electronic portal images (EPIs). The window and its 
gray levels were adjusted to optimize contrast for clear visualization of the lung border 
and skin border for the required measurements.  The length  of the treatment field was 
noted and distances were measured at the centre of the irradiated field.   A single 
observer i.e. the principal investigator evaluated all images to remove chances of any 
inter-observer bias. 
The CLD, CIW and CBESD were measured perpendicular to the chest wall along the 
central axis on medial and lateral tangential field DRR and EPIs. The average of the 
medial and lateral image values was taken for all measurements. The variation of lung 
tissue irradiated (CLD variation) was calculated by subtracting the CLD measured on 
electronic portal images (EPID) from the CLD measured on the DRR. 
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 CLD Variation = CLD(EPID) - CLD(DRR) 
 
The inter-fraction motion was correlated with patients' anxiety scores and other 
parameters like age, tumor location, type of surgery and duration of treatment. 
 
Statistical Analysis 
Categorical variables were summarised using counts and percentages. Quantitative 
variables were summarised using mean and standard deviation or median and 
range. Group systematic error (M), standard deviation of the systematic error (∑), and 
standard deviation of the random error (σ) were calculated using Van Herk method (101). 
Chi square test was used to compare the proportions between categorical variables. Two 
sample t tests was used to compare means between the two groups. Pearson correlation 
coefficient was used to find the correlation between two quantitative variables. For non-
normal variables, Mann Whitney’s U test was carried out. For all the analysis, 5% level 
of significance was considered to be significant. All the statistical analysis were done 
using stata/ic 13.1. 
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RESULTS 
 
From February 2016 to August 2016, 27 breast cancer patients seen in the Department of 
Radiotherapy who received adjuvant post mastectomy or whole breast radiation therapy 
with or without regional nodal irradiation by conformal technique were enrolled in the 
study after an informed consent.  Baseline data was collected including age, address of 
the patient, occupation, co-morbidities and any known history of anxiety disorder. 
Disease factors like clinical stage, pathological stage, type of surgery, neoadjuvant or 
adjuvant chemotherapy were recorded. These variables were obtained from the subjects 
by a direct interview and from their clinical records.  
 
Table 3  Patient characteristics 
PATIENT 
CHARACTERSTICS 
Number of       
patients 
(n=27) 
 % 
 
 
Age (years)    
 
Mean = 44 
Range:22-74  
 
 
     < 35    5 18.5 
     35-45    9 33.3 
     46-55  10 37.0 
     > 55    3 11.1 
 
Occupation 
  
    Housewife 22 81.5 
    Employed   5 18.5 
 
Stage 
  
     I   2   7.4 
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     IIA        2   7.4 
     IIB        7 25.9 
     IIIA        5 18.5 
     IIIB        5 18.5 
     IIIC        2   7.4 
     Tx   4 14.8 
 
Side of breast cancer 
  
     Right  11 40.7 
     Left  16 59.2 
 
History of anxiety 
disorder 
  
     Yes    1   3.7 
     No  26 96.3 
 
Co-morbidities 
  
     Hypertension   6 22.2 
     Diabetes Mellitus   6 22.2 
     Thyroid disorders   3 11.1 
     Bronchial asthma   0       0 
 
Surgery 
  
     Mastectomy  22 81.5 
     Breast conservation    5 18.5 
 
Axillary radiation 
  
     No  16 59.2 
     Yes  11 40.7 
 
No of  Fractions 
  
     15  16 59.2 
     25   11 40.7 
 
All patients had received systemic chemotherapy before being enrolled in this study.  
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The patients in this study were of varied age group, ranging from 22-74 years with mean 
age of 44 years. The maximum number of women were in the age group of 35-55 years 
(70.3%). 19% (n=5) women were working.  
 
 
Figure 12.  Percentage distribution of Age 
 
Majority of patients (77.7%) had Stage II - Stage III disease. 15 % patients (n=4) had an 
early stage breast cancer while 70% (n=19) patients presented with locally advanced 
breast cancer. Remaining 4 patients had undergone lumpectomy elsewhere and had 
presented to our institute for further management. Their initial staging was not known. 
Left sided breast cancer was more (59%, n=16) among our study patients. 
Six patients were known to have hypertension and six patients had diabetes mellitus. 
They all were on regular medications for the same. Three patients had thyroid disorders, 
< 35 
35-45 
46-55 
> 55 
19 % 
33 % 
37 % 
11 % 
Distribution of Age 
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one of them had hyperthyroidism and remaining two were hypothyroid.  None of the 
patients were known asthmatics. One patients was known to have an underlying anxiety 
disorder and was under follow up in Psychiatry department for the same. 
Most of the patients (81%) had undergone mastectomy, while only five (19%) patients 
underwent breast conservation surgery.  
 
 
 
Figure 13.  Type of surgery  
All patients received neo adjuvant or adjuvant chemotherapy and had completed their 
chemotherapy prior to being referred for loco regional radiation therapy. It was ensured 
that there was a gap of at least 3-4 weeks from date of completion of chemotherapy to the 
commencement of radiotherapy. Most of the patients had received anthracycline and 
taxane based chemotherapy. Some patients with triple negative breast cancer had also 
received platinum based chemotherapy. The patients with positive ER/PR receptor status 
were started on hormonal therapy prior to being referred for radiation therapy. They were 
continued on the same during the course of RT. Tamoxifen or Letrozole was started 
81.5% 
18.5% 
Surgery 
Mastectomy 
Breast conservation 
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depending on whether they were premenopausal or postmenopausal. Trastuzumab was 
also continued during the course of radiation therapy if the patients were Her2Neu 
positive.  
All patients received loco-regional radiation therapy with conformal technique. Field in 
field (FIF) technique with single isocentre was used for planning and treating all the 
patients. Prior to starting radiation therapy, pulmonary function test was done for all 
patients and an echocardiogram was done for left sided breast cancer patients. 
  
 
Figure 14.  Duration of Radiation therapy  
 
About 60% (n= 16) of the patients received hypofractionated radiotherapy 40 Gy in 15 
fractions over three weeks, while remaining 40% received conventional fractionation 
with a dose of 50 Gy in 25 fractions over 5 weeks. The mean duration of treatment for 
patients who received hypofractionated radiotherapy was 20.1 ± 2.3 days (excluding 5 
59.20% 
40.80% 
3 weeks  
5 weeks 
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more days of lumpectomy cavity boost) and mean duration of treatment for patients who 
received conventional fractionation was 37.6 ± 9.2 days. 
 
 
Figure 15.  Sites of Radiation therapy - chest wall or whole breast alone or with regional nodal 
irradiation. 
 
Among all the patients enrolled in this study, nearly 18% (n= 5) underwent whole breast 
irradiation, out of which 7% received an additional supraclavicular field irradiation in 
view of post neoadjuvant chemotherapy status.  None of the patients in this 
hypofractionated group received axillary radiation.  All the patients who had undergone a 
breast conservation surgery received hypofractionated radiotherapy. Out of 82% (n=22) 
of patients who received chest wall irradiation, half of them received axillary radiation 
due to various high risk factors like extranodal extension or incomplete axillary 
dissection. None of the patients received internal mammary nodal radiation. 
 
11 % 11 % 
30 % 
7.4 % 
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Chest wall Whole breast 
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Level of anxiety  
Beck Anxiety Inventory (BAI) score was calculated for each patient and level of anxiety 
was assessed. The baseline anxiety level of patients was considered on the basis of their 
anxiety score at the time of simulation. 45% of the patients had mild to moderate anxiety 
level at the baseline, while nearly 55% patients had minimal anxiety. None of the patients 
had severe anxiety at baseline. 
Anxiety level Number of patients (%) 
Minimal 15  (55.5) 
Mild 11  (40.7) 
Moderate   1    (3.7) 
Severe   0 
 
The variation of anxiety score over the course of treatment was noted for each patient. 
The median anxiety score at the time of simulation and on the first day of radiation 
therapy delivery was 7. It showed a decreasing trend in the subsequent days. The median 
score was 4 and 3 for second and third day of treatment respectively. Figure 16 shows the 
mean and range of anxiety score for all patients during the course of treatment.  
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Figure 16.  Mean and range of anxiety score during the course of treatment. Triangle represents the 
mean anxiety score for that particular day.  
 
Nearly half of the patients had mild to moderate anxiety level at the time of simulation 
and first day of treatment with 7% patients developing severe anxiety on the 1
st
 day (Day 
1) of radiation therapy. As the radiation therapy course progressed, the proportion of 
patients with mild to moderate anxiety reduced. All patients had a very low anxiety score 
during the last week of treatment. This is depicted in the following table 6 and figure 17. 
The patient with an underlying anxiety disorder had mild anxiety at simulation. Her 
anxiety score was constant throughout the course of treatment with no typical decline as 
seen in other patients.  
Table 4.  Percentage of patients in each anxiety group during simulation and course of treatment. 
Anxiety level  Minimal 
     % 
 Mild  
   % 
Moderate 
     %  
Severe 
   % 
6.9 
8.4 
4.4 3.7 3.6 2.9 3.1 2.2 
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30 
At 
Simulation 
Day 1 Day 2 Day 3 Week  2 Week  3 Week 4 Week 5 
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At simulation  56 41 4 0 
Day1  56 37 0 7 
Day2  78 22 0 0 
Day3  89 7 4 0 
Week 2  85 15 0 0 
Week 3  89 11 0 0 
Week 4  91 9 0 0 
Week 5  100 0 0 0 
 
 
Figure 17. Variation of anxiety level among patients during radiation therapy.  
Each color shade is representative of an anxiety level and the width of each color represents the 
percentage of patients with that anxiety level on a particular day of treatment. The blue are is seen 
to be increasing with time, while red area reduces, green and purple areas are seen only during the 
initial days of treatment.  
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There is a rapid decline in the anxiety from the first day of treatment to the end of 
treatment. Following figure 18 shows this rapid decline for 2 of our patients who had 
score of more than 26 on the first day of treatment. 
 
Figure 18. Rapid reduction in anxiety score for 2 of our patients who had severe anxiety level at the 
start of treatment. 
 
 
Inter-fraction variations 
A total of 27 pair of DRRs and 577 Electronic portal images (EPI) were evaluated. Mean 
central lung distance on DRR was 2.34 cm (Range: 1.4-3.5 cm). Table 7 shows the 
results for inter-fraction variability observed in these 27 patients.  
 
Day 1 Day 2 Day 3 Week 2 Week 3 Week 4 Week 5 
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Table 5. Group Systematic error (M), Standard deviation of systematic error(∑) , Standard 
deviation of random error (σ ) (mm) 
 
Parameter 
 
M 
 
∑ 
 
 σ 
 
 Maximum deviation 
 
Vertical 
 
3.4 
 
1.8 
 
2.8 
 
      11.4 
Lateral 3.4 1.8 2.8       11.5 
Longitudinal 3.0 1.0 2.4       11.2 
CLD variation 3.1 1.8 3.1       11.8 
 
 
The vertical, lateral and longitudinal shifts varied with a mean and SD of 3.4±1,8mm, 
3.4±1.8 mm and 3.0± 1.0 mm respectively. The variation detected was similar in all 
directions. The random error varied from 2.4 to 2.8 mm. 
CLD variation which represented the inter-fraction variation of lung involvement was 
calculated from electronic portal images by comparing with baseline CLD measured on 
the reference DRR. The average systematic deviation was 3.1±1.8mm, ranging from 
0.11-0.88mm among the patients. The maximum deviation observed was 11.8mm. The 
random error observed (σ) was 3.1mm. 
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Figure 19. Histogram showing CLD variation for all patients had a normal distribution with 95% 
of values between -0.5 mm and 6.7 mm. 
 
Table 6. Magnitude of all CLD variation. Only 2.8% values were more than 10mm. 
 < 5mm 5-10mm >10mm 
CLD difference (n=140) 80.7 %  16.4% 2.8% 
 
 
Figure 20 shows the vertical, lateral and longitudinal variation during the course of 
treatment. It was almost the same and did not show any variation with decrease in anxiety 
level.  The figure also shows that the CLD variation showed a downward trend over the 
first three days of treatment, with a mild increase in the second week of treatment and 
thereafter remained almost similar during subsequent weeks. 
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Figure 20. Variation in mean of different parameters during the course of treatment 
 
Mean CIW for chest wall irradiation was 4.6 cm and mean CIW for whole breast 
irradiation was 7.6 cm. The average day to day variation observed was  3.3 mm (Range: 
0.7 - 9.6 mm).   
Mean CBESD was 2 cm. The maximum variation observed was up to 6 mm. This central 
flash distance or CBESD was kept 2 cm during the planning.  Thus, with an average 
variation of 2.3 mm observed in our patients, there are no chances of missing the target.  
Table 7. Day to day variation of parameters (mm) 
      Average variation Range of variation 
 
CIW 
 
3.3 
 
0.7 - 9.6 
0 
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1 
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2 
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3 
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4 
4.5 
5 
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Inter-fraction variation 
Vertical Lateral Longitudinal CLD 
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CBESD 2.3 0.8 - 6.1 
 
 
Figure 21. Correlation between CIW and other two parameters (CLD and CBESD) measured for a 
single patient. (r= 0.97 and -0.72) 
Correlation of anxiety score with CLD variation 
 
The anxiety score on the first day of treatment was found to be significantly correlating 
with CLD variation observed on the first day of treatment (r=0.45, p=0.02). The 
correlation between the two variables was not significant for the subsequent days. 
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Figure 22.  Scatter plot of Day 1 anxiety score variation with Day 1 CLD variation. 
 
 
Inter-fraction CLD variation when compared with baseline anxiety level of minimal 
versus mild to moderate anxiety was not found to be significant. (p =0.38). 
Table 8. Mean, median and range of CLD variation for patients with minimal versus mild to 
moderate baseline anxiety level 
 Mean systematic 
error 
Median Range 
Minimal anxiety 3.0 2.8 1.7-5.0 
Mild to moderate anxiety 3.2 2.4 1.1-8.8 
 
 
r = 0.45 p = 0.028
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Figure 23. Mean CLD variation for patients with minimal versus mild to moderate anxiety level. 
 
 
 Anxiety score and other parameters 
 
An attempt was made to find any predictable factors of anxiety level noted in patients. 
There was no significant correlation found between anxiety score and age (r=0.16, p= 
0.4). Anxiety level among patients with mastectomy versus breast conservation surgery 
did not show any significant difference (p= 0.43). No significant difference was found 
between anxiety level and duration of radiation therapy (p=0.48). 
Anxiety level among working women and housewives was not significantly different. 
27% women with minimal anxiety level were working while 9% women with mild 
anxiety level were working.  
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CLD variation and other parameters 
The CLD variation recorded was not significantly different for the type of surgery or the 
duration of treatment. No significant differences could be found in the inter-fraction 
motion observed between patients with left or right-sided breast cancer. 
The following two Figures 24 and 25 show the inter-fraction variability in terms of CLD 
for each patient over the course of treatment. It is represented separately for 3 weeks 
versus 5 weeks of treatment. The CLD variability did not show any pattern and was 
found to be random. For majority of the patients, the values lied within 5mm and it varied 
less among patients who received 5 weeks of treatment compared to those who received 3 
weeks of radiation therapy. However, with statistical analysis, the p value was not 
significant (p=0.4).  
 
Figure 24. CLD setup variability for each patient who received 3 weeks of treatment 
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Figure 25.  CLD setup variability for each patient who received 5 weeks of treatment 
 
The correlation coefficient between age and CLD variation showed an inverse relation 
(r= -0.26), however it was not found to be significant ( p = 0.18). 
 
Figure 26.  Scatter plot to show CLD variation (mm) with increasing age (years). 
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There was a significant correlation between baseline CLD values and mean variation in 
CLD. As the baseline CLD value increased, it showed a higher mean inter-fraction 
variation (r=0.56, p= 0.002). 
 
 
Figure 27. Scatter plot of CLD variation (mm) with baseline CLD values (cm) 
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DISCUSSION 
 
Radiation therapy has an important role in treatment of breast cancer. It is indicated in all 
patients after breast conservation surgery and for high risk patients after mastectomy. 
Non metastatic breast cancer patients referred for loco-regional radiation therapy and 
who were treated with conformal technique were included in this study.   
Most of our patients (70%, n=19) presented with locally advanced breast cancer. These 
patients and 3 of the 4 patients who had lumpectomy elsewhere(Tx) underwent 
mastectomy. Only 18% (n=5, including one of those who had lumpectomy elsewhere) of 
our patients had breast conservation surgery. In our country the psychological factors 
about having the organ with cancer tissue removed are more significant than cosmetic 
concerns. Also, the patients come from far off places and have a poor adherence to follow 
up regimens.  
  
 
Level of anxiety 
Various studies have evaluated and recorded anxiety levels in cancer patients and more 
so for patients undergoing radiation therapy. Studies have looked into anxiety level for 
cancer patients of various sites(77). 
 
With our study, we wanted to focus on breast cancer patients which is the most common 
cancer among women and has a significant morbidity and mortality rate. Breast cancer 
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requires aggressive treatment of prolonged duration with surgery, radiation therapy, 
chemotherapy, hormonal therapy during which the patients experience innumerable side 
effects including psychological distress(76,79).  
 
Our results showed that 44% (n=12) of patients had mild to moderate anxiety levels at the 
time of simulation and none of the patients had severe anxiety level. However, on the 
first day of treatment 37% (n= 10) of patients had mild anxiety level with 7.4% (n=2) of 
patients having severe anxiety level. This anxiety reduced rapidly in the subsequent 
radiotherapy sessions with only 11% (n=3) and 15% (n=4) of patients having mild to 
moderate anxiety levels by third day of radiation therapy and second week of treatment 
respectively. This trend was similar to results of Lewis et al. who showed patients' 
anxiety levels were highest at radiotherapy simulation and first session with a rapid 
decline after that (68). Halkett et al. looked into the information needs of breast cancer 
patients as they proceed through radiotherapy and also found a higher anxiety at baseline 
which did not drop until after commencement of treatment (80). 
 
Relatively higher anxiety levels seen at the time of simulation and starting of 
radiotherapy may be explained by the uncertainty among patients about the whole 
procedure, fear of unknown, fear of pain or damage to body and characteristics of 
radiotherapy environment.  For the treatment, the patients need to change into a different 
set of clothes and there is a need to expose the tattoos for their accurate positioning on the 
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machine. There are more number of quality assurance checks with more number of 
people on the machine during the first day of treatment. All these would have contributed 
towards increased anxiety among patients. Prior to starting treatment, the patients are 
explained about the likely acute and late side effects of radiation therapy and an informed 
consent is taken. They hence have a fear of likely side effects like getting skin burns or 
damage to lungs or heart with the treatment. Radiation therapy has various nicknames in 
local languages varying from 'heat' to 'current' treatment. The patients overhear these 
words while being unfamiliar with the actual technique and machines. This makes them 
more nervous and overwhelmingly worried about the treatment and this may be 
manifested as an array of physical symptoms and signs.  
 
The anxiety levels drop rapidly post treatment commencement and during the course of 
treatment as they become habitual and familiar with the procedure and due to absence of 
their perceived side effects. 
 
Wide variation in anxiety level was seen among our patients during the planning and start 
of treatment while there was low anxiety score for all patients by the end of treatment. 
Fifty six percent patients had only minimal anxiety at the time of simulation and on the 
first day of treatment. This could be due to the support from the radiation therapy team 
including the technologists and nursing staff present at the time of planning and treatment 
delivery which helps them to relax. At our institution, most of the patients are from far 
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off places and as cancer therapy is a prolonged treatment, they stay back here for months 
during the course of treatment in nearby hotels during which they tend to interact with 
other patients undergoing radiation therapy.  They discuss with other patients about their 
experience of radiation therapy and this might have assured them of absence of perceived 
side effects. This may be a contributory factor to low levels of anxiety level observed in 
few patients when they first came for radiotherapy planning and treatment. It may be 
contradictory to other studies where patients may not have had a similar environment of 
discussion. 
 
The patients are referred for radiation therapy after having completed their systemic 
chemotherapy.  In the current standard of care, anthracyclins, taxanes and platinum based 
chemotherapy is used for all the patients. We observed that many of our patients had 
chemotherapy induced neuropathy. This may be a confounding factor in recording the 
anxiety score as tingling and numbness which is one of the item in BAI questionnaire 
was found to be severely bothering the patients, which could be likely due to post 
chemotherapy neuropathy rather than anxiety. The neuropathy improved over the course 
of treatment. 
 
The type of anxiety experienced by the patients in our study was more due to stress of a 
new event and it settled with habituation of the situation. Thus, it is more likely an 
anticipatory anxiety seen in breast cancer patients during radiotherapy. 
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We attempted to further look into factors which may predict the level of anxiety among 
patients like their age, occupation, type of surgery and duration of treatment. However, 
no significant difference was found in the anxiety level and these specific parameters. 
 
Inter-fraction variations 
Treatment delivery precision is the backbone of radiotherapy treatment in this era of 
conformal techniques. Breast or chest wall irradiation is one of the most challenging 
radiotherapy plans due to the complexity in shape of the breast and postoperative chest 
wall, underlying normal structures like lung and heart and target motion due to 
respiratory movements. With the multimodality treatment, cure rates in breast cancer are 
higher and patients live longer. This demands a need to minimize the radiation dose to 
lung and heart tissue to prevent any long term toxicity in breast cancer survivors. Thus to 
achieve this, various conformal techniques have evolved and position verification has 
become an important aspect of treatment. It includes quality assurance measures, 
ensuring treatment delivery as per the plan, daily reproducibility of position and 
accounting for target motion due to breathing.  
 
At our institution, machine based and patient based quality assurance measures are 
practiced. Setup sheets are maintained and each treatment volume and plan is verified by 
at least two physicists and one radiation oncologist. Breast board is used for 
immobilization for all breast cancer patients. It has an adjustable incline with varying 
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wedge angle and is helpful for excluding the lung and heart to the maximum extent 
possible from the treatment volume. However, due to the incline and hand grip of the 
breast board, it may allow patients’ movement and can produce a difficulty in 
reproducing exactly the same position. This may account for some inter-fraction 
variations. Thus, additional supports like knee support and heel lock for some patients or 
other supports like body cast or Vacloc have been tried at many centers.  
  
Inter-fraction variations are expected to be seen during treatment of breast cancer patients 
due to the setup changes, patient movements and breathing movements. Small magnitude 
inter-fraction variations up to 5mm are taken care of in the planning process and has little 
clinical impact on breast radiation therapy.   
  
Lawson et al (95) had reported systematic error of less than 2 mm with standard deviation 
of 4.1, 3.1 and 3.7 mm in vertical, lateral and longitudinal direction respectively. In our 
study, we found that group systematic error was less than 5 mm with standard deviation 
of 1.8, 1.8 and 1.0 mm in vertical, lateral and longitudinal direction respectively. Only 
3.6% shifts were 1 cm or larger with no shifts more than 2 cm unlike Lawson et al who 
had 13 vector shifts of larger than 2 cm. The shifts that we observed in our study were 
random with no predictable pattern in the vertical, longitudinal and lateral shifts recorded, 
and it did not diminish as the treatment progressed.  The random errors were within 3 mm 
for all three directions.  
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The group systematic error for CLD was 3.1 mm with standard deviation (∑) of 1.7 mm 
and a maximum deviation of 11.8 mm. We noted that 95% of variation in CLD was 
between 0.5 - 6.7 mm.  This describes the uncertain movement due to breathing motion. 
The CLD variation observed was higher in our study compared to other similar studies. 
The average systematic difference observed by Prabhakar et al. for CLD was 1.2 mm (∑ 
of 0.7 mm with maximum deviation of 2.2 mm). Lirette et al. reported an average 
difference of 1 mm but a larger standard deviation ∑ of 3.1 mm and maximum deviation 
of 7.4 mm. In our study, the observed standard deviation of random error (σ) in CLD was 
3.1 mm which was similar to that observed by Koseoglu et al. (102). Only 2.8% values 
showed a CLD deviation of 1 cm or more. 
 
The observed day to day mean variation for CBESD or central flash distance was 2.3 mm 
with maximum deviation of 6.1 mm. Thus, keeping a margin of 2 cm during planning to 
account for breathing movements will ensure no cold regions during delivery of radiation 
therapy due to variation in chest wall expansion. This is similar to previously reported 
value of 2.5 mm by Prabhakar et al. (103) and 2.2 mm reported by Van Tienhoven et al. 
(104). 
The inter-fraction variation in central irradiated width (CIW) was 3.3 mm in our study 
and this was slightly more than 2.1 mm reported in study by Prabhakar et al. and similar 
to value (3.4 mm) reported by Lirette et al. (105).  
 
As infrequently, deviations larger than the acceptable values could occur during treatment 
and these could significantly change the irradiated volume by under dosage of the target 
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and high dose to the normal structures.  It suggests a need for daily position verification 
or other methods like DIBH, active breathing control, gating etc to ensure radiation as per 
the planned volumes. Daily position verification using electronic portal imaging 
(orthogonal and tangential field images) in our study was useful and a simple technique. 
 
It was hypothesized that inter-fraction variability will be more for patients with a higher 
anxiety level due to the changes in respiratory rate and tidal volume that is influenced by 
increased output at the medullary level in anxious patients. Our study found a significant 
correlation between anxiety score and variations observed in CLD from the baseline on 
the first day of treatment (r=0.45, p=0.02). A patient is relatively more anxious at the start 
of treatment and this influences the breathing pattern during treatment. These variations 
in breathing pattern translates to more shifts recorded on the first day of radiotherapy. 
This subsequently reduced during the course of treatment but showed no predictable 
pattern or significant correlation with the observed anxiety scores. 
 
Kron et al. had conducted a study on 20 patients to look into intra-fraction and inter-
fraction variability and found inter-fraction variation to be twice as large as intra-fraction 
variation. Thus looking at their study, they concluded that as there is a relatively smaller 
intra-fraction variation, the breast cancer patients may not considerably benefit from 
breath holding or gated techniques. They reported an inter-fraction variation in lung 
movement by 1.8 mm with a standard deviation of 0.7 mm. These values were lesser than 
the observed values in our study. They also looked for any correlation between set-up 
errors and patient parameters like age, treatment side, weight, height or breast separation. 
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They found that increasing age was significantly correlated with inter-fraction motion (p 
= 0.05). They assumed this may be due to more inflexibility and difficult in holding 
position for longer time in older patients.  Contrary to above data, our study showed a 
negative correlation between increasing age and CLD variation i.e. with increase in age, 
variation in CLD variation was less (p=0.18). Kron et al. did not find statistical 
correlation with other parameters.  In our study also, the variation in CLD was not 
significantly different for left and right sided breast cancer, type of surgery undergone 
and duration of treatment.  
 
There was a significant correlation between the baseline CLD value and variation 
observed in CLD (p=0.002). A larger CLD showed a greater variation in day to day 
treatment. This could be likely due to changes in the breathing pattern. 
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CONCLUSION 
 
   This study has given us an estimate of the anxiety level among breast cancer patients 
who have undergone radiation therapy using the conformal technique in our 
department. It has given us an insight into psychological stress of patients just prior 
to and while on treatment.  
 
    Anxiety alters the breathing pattern and in breast cancer radiotherapy, chest wall 
movements due to respiratory motion is an important contributory factor to inter-
fraction variation. Central lung distance variation compared to baseline was found to 
be more on the first day of treatment and was significantly correlated with higher 
level of anxiety seen at starting of treatment.  
 
  .There is a need of care and support of patients by the radiation oncologist and other 
support staff to reduce anxiety levels which has been shown to peak at the time of 
simulation and first day of treatment.  
 
   The day before starting of radiation therapy can be the treatment verification day 
whereby the positioning and other parameters are checked without actual delivery of 
treatment which could help the patients to get accustomed to the treatment 
environment.  
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   Communication with patients is a key factor. Patients should be educated about 
radiation therapy, its procedure at simulation and treatment. We suggest counseling 
and use of patient information leaflets with pictorial representation.  
 
   It is also important for the oncology team to be able to recognize patients with higher 
anxiety levels who may need to be referred to psychiatrist for further evaluation and 
counseling. 
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APPENDIX I 
 
 
AJCC TNM Staging for Breast Cancer 
T Staging 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
Tis (DCIS) 
Tis (LCIS) 
Ductal carcinoma in situ 
Lobular carcinoma in situ 
Tis (Pagets) 
Paget disease of the nipple not associated with invasive 
carcinoma and/or carcinoma in situ (DCIS and/or LCIS) in the 
underlying breast parenchyma. 
T1 Tumour 2 cm or less in greatest dimension 
T1mic 
Microinvasion 0.1 cm or less in greatest 
Dimension 
T1a 
More than 0.1 cm but not more than 
0.5 cm in greatest dimension 
T1b 
More than 0.5 cm but not more than 1 cm in 
greatest dimension 
T1c 
More than 1 cm but not more than 2 cm 
in greatest dimension 
T2 
Tumour more than 2 cm but not more than 5 cm in greatest 
dimension 
T3 Tumour more than 5 cm in greatest dimension 
T4 
Tumour of any size with direct extension to chest wall and/or to 
skin (ulceration or skin nodules) 
T4a Extension to chest wall (does not 
include pectoralis muscle invasion only) 
T4b Ulceration, ipsilateral satellite skin nodules, 
or skin oedema (including peau 
d’orange) 
T4c Both 4a and 4b 
T4d Inflammatory carcinoma 
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N Staging 
cNx Regional lymph nodes cannot be assessed 
cN0 No regional lymph node metastasis 
cN1 
Metastasis in movable ipsilateral Level I, II axillary lymph 
node(s) 
cN2 
Metastasis in ipsilateral Level I, II axillary lymph node(s) that are 
clinically fixed or matted; or in clinically detected ipsilateral 
internal mammary lymph node(s) in the absence of clinically 
evident axillary lymph node metastasis 
cN2a Metastasis in axillary lymph node(s) fixed to one 
another (matted) or to other structures 
cN2b Metastasis only in clinically detected internal 
mammary lymph node(s) and in the absence of 
clinically detected axillary lymph node metastasis 
cN3 
Metastasis in ipsilateral infraclavicular (Level III axillary) lymph 
node(s) with or without Level I, II axillary lymph node 
involvement; or in clinically detected ipsilateral internal 
mammary lymph node(s) with clinically evident Level I, II 
axillary lymph node metastasis; or metastasis in ipsilateral 
supraclavicular lymph node(s) with or without axillary or internal 
mammary lymph node involvement 
cN3a Metastasis in infraclavicular lymph node(s) 
cN3b Metastasis in internal mammary and axillary 
lymph nodes 
cN3c Metastasis in supraclavicular lymph node(s) 
  
 
M Staging 
Mx Not assessed 
M0 No distant metastasis 
M1 Distant metastasis 
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Pathological N Staging 
pNx Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
pN1 
Micrometastasis; or metastasis in 1–3 axillary ipsilateral lymph 
nodes; and/or in internal mammary nodes with metastasis detected 
by sentinel lymph node biopsy but not clinically detected 
pN1mic Micrometastasis (larger than 0.2 mm and/or more than 
200 cells, but none larger than 2.0 mm) 
pN1a Metastasis in 1–3 axillary lymph node(s), including at 
least 1 larger than 2 mm in greatest dimension 
pN1b Internal mammary lymph nodes with microscopic or 
macroscopic metastasis detected by sentinel lymph 
node biopsy but not clinically detected 
pN1c Metastasis in 1–3 axillary lymph nodes and internal 
mammary lymph nodes with microscopic or 
macroscopic metastasis detected by sentinel lymph 
node biopsy but not clinically detected 
pN2 
Metastasis in 4–9 ipsilateral axillary lymph nodes, or in clinically 
detected ipsilateral internal mammary lymph node(s) in the absence 
of axillary lymph node metastasis 
pN2a Metastasis in 4–9 axillary lymph nodes, including at 
least one that is larger than 2 mm 
pN2b Metastasis in clinically detected internal mammary 
lymph node(s), in the absence of axillary lymph node 
metastasis 
pN3 pN3a 
Metastasis in 10 or more axillary lymph nodes (at least 
one larger than 2 mm) or metastasis in  infraclavicular 
lymph nodes 
pN3b 
Metastasis in clinically detected internal ipsilateral 
mammary lymph node(s) in the presence of positive 
axillary lymph node(s); or metastasis in more than 3 
axillary lymph nodes and in internal mammary lymph 
nodes with microscopic or macroscopic metastasis 
detected by sentinel lymph node biopsy but not 
clinically detected  
pN3c 
Metastasis in ipsilateral supraclavicular lymph node(s) 
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STAGE GROUPING 
Stage T Stage N Stage M Stage 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0, T1 N1mic M0 
IIA T0, T1 N1 M0 
T2 N0 M0 
IIB T2 N1 M0 
T3 N0 M0 
IIIA T0, T1, T2 N2 M0 
 T3 N1, N2 M0 
IIIB T4 N0, N1, N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
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RTOG breast contouring guidelines for breast and chest wall 
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RTOG contouring guidelines for regional nodal volumes for breast cancer 
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APPENDIX III 
 
INFORMATION SHEET AND CONSENT FORM 
Level of anxiety in breast cancer patients receiving locoregional radiation therapy 
and its correlation with inter-fraction variations observed during delivery of 
treatment 
Department of Radiotherapy 
Christian Medical College, Vellore 
 
Patient Information Sheet 
Breast cancer treatment is a multimodality approach where surgery is followed by 
adjuvant therapy with chemotherapy, radiation therapy and hormonal therapy based on 
the risk factors.  You have been referred for radiation therapy after the surgery.  
Radiotherapy is an important part of the breast cancer treatment as it helps to prevent 
recurrent disease and this has been proven by various studies in the past.  
You are expected to be anxious about the radiation therapy and may have various 
questions in your mind.  Radiation therapy to breast cancer patients is directed either on 
the residual breast tissue (in cases of early breast cancer following lumpectomy) or to the 
chest wall (in cases radiation therapy is being delivered following removal of the whole 
breast). It is given using X rays and the treatment is not painful. The procedure requires 
you to lie down as instructed using an immobilisation device.  Prior to starting the 
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treatment, you will be required to come for planning for 1 day which will be done in the 
same position as the treatment followed by a CT scan for treatment planning. Once the 
plan is ready, your treatment will be started.  
The radiotherapy planning and execution in breast cancer patients depends on the amount 
of chest wall expansion and therefore during planning adequate margins are given so that 
there are no areas in planning field that are missed. You are being given the most 
accurate form of radiation therapy. Prior to starting treatment images will be taken for 
verification of your position and to assess any deviation from the original radiotherapy 
plan. These images will be taken again weekly. This will ensure that treatment is being 
delivered correctly to the target volumes.  
This observational study will help us to understand the levels of anxiety of breast cancer 
patients undergoing radiation therapy and will help us to suggest the need of suitable 
interventions to decrease anxiety. This will also try to see if the level of anxiety correlates 
with the change in respiratory pattern of the patients.  
We request you to participate in this study. Being part of the study you will be required to 
fill up a questionnaire on the day of planning, first three days of radiation treatment and 
weekly once to assess the level of anxiety. The standard protocol for treatment is 
followed with no change in the delivery of treatment if you agree to be a part of this 
study. The only difference is the extra images taken for verification of position prior to 
treatment. This may ensure more accurate delivery of radiation to target volumes. 
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What is radiotherapy? 
It is a treatment given using X-rays and it is not painful. It requires you to lie down as 
instructed using an immobilisation device. 
How does radiotherapy help in breast cancer? 
Radiotherapy is an important part of the breast cancer treatment as it helps to prevent 
local recurrence of the disease 
What are the side effects with radiation? 
Acute side effects may occur while you are undergoing radiotherapy. These include 
darkening of the skin, peeling of the skin and ulcers over the radiated region.  
Late side effects may occur months or years after completion of radiation therapy. These 
include skin tightness due to fibrosis, lymphedema, lung problems like radiation 
pneumonitis and heart problems (for left sided breast cancer patients) like 
cardiomyopathy. 
What is this study? 
This study tries to understand the levels of anxiety of breast cancer patients undergoing 
radiation therapy and help to suggest the need of suitable interventions to decrease 
anxiety. This will also try to see if the level of anxiety correlates with the change in 
respiratory pattern of the patients.  
If you take part what will you have to do?  
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If you agree to participate in this study, you will have to sigh the consent form. You will 
be required to fill up a questionnaire on the day of planning, first three days of radiation 
treatment and weekly once to assess the level of anxiety. 
Will there be any difference in treatment in this study? 
The standard protocol for treatment is followed with no change in the delivery of 
treatment if you agree to be a part of this study. The only difference is the extra images 
taken for verification of position prior to treatment. This may ensure more accurate 
delivery of radiation to target volumes. The radiation dose delivered due to the extra 
images is very minimal and will be delivered only to the treatment field. Thus, no extra 
side effects are expected. 
Will you get more side-effects if you participate? 
As there is no difference in the treatment, no extra side effects are expected. 
Can you withdraw from this study after it starts?  
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your 
usual treatment at this hospital in any way.  
What will happen if you develop any study related injury?  
Since this is an observational study, no particular study related side effects are expected.  
Will your personal details be kept confidential? 
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The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, people 
associated with the study may review your medical notes without your additional 
permission. 
 Whom will you contact for study related queries? 
If you have any further questions, please ask Dr. Shina Goyal. 
Ph No: +91-9843673938, email: shina.goyal@cmcvellore.ac.in 
 
 
 
 
Informed Consent 
Study Title:  Level of anxiety in breast cancer patients receiving locoregional radiation 
therapy and its correlation with inter-fraction variations observed during delivery of 
treatment 
 
Study Number: ____________ 
Subject’s Initials: __________________  
Subject’s Name: _________________________________________ 
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Date of Birth / Age: ___________________________ 
i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask questions. 
[  ] 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
(iii)  I understand that Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the trial. I agree to this access. However, I understand that my identity will 
not be revealed in any information released to third parties or published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________          
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Signature:  
Or 
 
 
 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature or thumb impression of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name & Address of the Witness: ______________________________ 
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APPENDIX V 
Data Sheet 
 
 
uniqueid age occupation diagside ct cn pt pn surg ht dm thy ba oth anxiety sites dose frac dosim dos doc b4sim anxiety level basd1
1 62 1 1 1 0 2 2 2 2 2 2 2 4 1 1 04/04/2016 15/04/2016 05/05/2016 8 mild 0
2 46 1 1 4 1 1 1 1 2 2 2 2 2 2 3 2 2 30/03/2016 12/04/2016 16/05/2016 2 minimal 4
3 33 1 1 1 0 1 0 2 2 2 2 2 2 2 4 1 1 15/02/2016 29/02/2016 18/03/2016 10 mild 27
4 36 1 1 5 0 1 1 1 2 2 2 2 2 2 3 2 2 08/02/2016 25/02/2016 31/03/2016 20 moderate 27
5 74 1 2 4 1 3 2 1 1 2 1 2 1 2 3 2 2 26/02/2016 18/03/2016 25/04/2016 8 mild 7
6 49 2 2 2 1 2 1 1 2 2 1 2 2 2 3 2 2 02/03/2016 17/03/2016 22/04/2016 5 minimal 7
7 49 2 2 2 1 2 0 2 1 2 1 2 2 2 4 1 1 16/03/2016 29/03/2016 26/04/2016 1 minimal 0
8 40 1 1 2 2 2 2 1 2 2 2 2 2 2 3 2 2 22/02/2016 10/03/2016 14/04/2016 1 minimal 6
9 42 1 2 4 1 2 3 1 1 1 2 2 2 2 3 2 2 06/04/2016 21/04/2016 25/06/2016 7 minimal 7
10 42 1 2 2 1 1 2 1 2 2 2 2 2 2 2 1 1 28/03/2016 08/04/2016 28/04/2016 12 mild 9
11 45 1 2 2 0 3 1 1 2 2 2 2 2 1 2 1 1 08/04/2016 25/04/2016 13/05/2016 9 mild 11
12 44 1 1 5 0 0 0 1 2 1 2 2 2 2 2 1 1 04/04/2016 19/04/2016 09/05/2016 4 minimal 4
13 46 1 2 2 1 2 1 1 2 2 2 2 2 2 2 1 1 10/02/2016 26/02/2016 17/03/2016 9 mild 10
14 58 1 1 2 1 2 0 1 2 1 2 2 2 2 1 1 1 15/04/2016 04/05/2016 24/05/2016 5 minimal 3
15 35 1 1 4 1 2 3 1 2 2 2 2 2 2 3 2 2 18/04/2016 28/04/2016 01/06/2016 2 minimal 1
16 39 1 2 3 1 1 0 1 2 2 2 2 2 2 2 1 1 02/05/2016 12/05/2016 01/06/2016 6 minimal 14
17 31 2 2 2 1 5 1 1 2 2 2 2 2 2 1 1 1 22/04/2016 11/05/2016 31/05/2016 7 minimal 5
18 34 1 2 2 2 2 1 1 2 2 2 2 2 2 2 1 1 20/04/2016 04/05/2016 24/05/2016 2 minimal 7
19 33 1 2 5 0 5 1 1 2 2 2 2 2 2 2 1 1 02/05/2016 20/05/2016 10/06/2016 2 minimal 5
20 47 1 2 4 3 2 1 1 1 1 2 2 2 2 3 2 2 23/05/2016 07/06/2016 13/07/2016 13 mild 11
21 52 1 2 4 3 4 2 1 1 2 2 2 2 2 3 2 2 18/05/2016 06/06/2016 09/07/2016 6 minimal 10
22 22 1 2 3 1 2 1 1 2 2 2 2 2 2 3 2 2 27/05/2016 14/06/2016 18/07/2016 1 minimal 2
23 48 2 2 4 1 1 2 1 1 2 2 2 2 2 3 2 2 06/06/2016 22/06/2016 26/07/2016 8 mild 10
24 46 1 1 3 1 1 0 1 2 1 2 2 2 2 2 1 1 22/06/2016 05/07/2016 25/07/2016 9 mild 11
25 36 2 1 2 1 1 0 2 2 2 2 2 2 2 5 1 1 01/07/2016 11/07/2016 28/07/2016 6 minimal 3
26 52 1 2 2 0 1 0 1 2 2 2 2 2 2 1 1 1 20/06/2016 30/06/3016 20/07/2016 9 mild 10
27 48 1 1 5 0 2 1 2 2 1 2 2 2 2 5 1 1 04/07/2016 15/07/2016 04/08/2016 13 mild 15
basd2 basd3 baswk2 baswk3 baswk4 baswk5 apd1 apd2 apd3 apwk2 apwk3 apwk4 apwk5 latd1 latd2 latd3 latwk2 latwk3 latwk4 latwk5 ccd1 ccd2
0 0 0 0 0.1 0 0 0 0.2 0 0.1 0 0 0.2 0.5 0.1
8 2 3 3 6 3 0.2 0.1 0.2 0 0.1 0.3 0 0.1 0.2 0.1 0.3 0.3 0.2 0.1 0.7 0.1
8 3 6 1 0.1 0.1 0 0 0.5 0.3 0.1 0.4 0.3 0.7 0.4 0.7
15 18 14 9 8 6 0.1 0 0.4 0 0 0.5 0.5 0.7 0.1 0.3 0.5 0.2 0.2 0.1 0.4 0.1
2 2 2 2 2 0 0.6 0 0.2 0.6 0.3 0.3 0.3 0 0 0.1 0.6 0.4 0.2 0.6 0 0.2
5 5 9 4 5 5 0.5 0.4 0.2 0 0.1 0.3 0.1 0.2 0.1 0.2 0.4 0.2 0.1 0.3 0.3 0.2
0 4 2 0 0.4 0.1 0.5 0.2 0.3 0 0.6 0.4 0.6 0.1 0.1 0.4
0 0 0 1 0 0 0.2 0.2 0.3 0.8 1 0.4 0.3 0.1 0.2 0 0.4 0.1 0.2 0.3 0.5 0.5
3 0 1 2 2 2 0 0.8 0.5 0.5 0.2 0.2 0.5 0.6 0.7 0.6 0.3 0.1 0.2 0.5 0 0.1
8 3 8 8 0.1 0.1 0.7 0.2 0 0.3 0.3 0.4 0.5 0.3 0.3 0
4 10 10 13 0.8 0.2 0.2 0.1 0.1 0.3 0.6 0 0 0 0.3 0.3
4 3 3 4 0 0.2 0.6 0.6 0 0.6 0.2 0.3 1 0.6 0.3 0.6
3 6 3 3 0.2 0.1 0.5 0.3 0 0.7 0.2 0.5 0.2 0.9 0.2 0.1
4 1 0 0 0.3 0.2 0.4 0 0 0.7 0 0.2 0 0.2 0.7 0
0 1 0 1 1 0 0.5 0.3 0.6 0.3 0.5 0.1 0.3 0.7 0.7 0.5 0.6 0.4 0.7 0.9 0.5 0.1
4 3 6 4 0.7 0.1 0.3 0.3 1.3 1.1 0.2 0.1 0.5 0.3 0.7 0.4
0 0 0 0 1.2 0.6 0.1 1 0.3 0.4 0 0.5 0 0.4 0.1 0.4
4 1 2 2 0.3 0.7 0.7 0.5 1.4 0.2 0.2 0.3 0.2 0.9 0.2 0.8
2 3 5 2 0.6 0.6 0 0.7 0 0.8 0.9 0 1.2 1.4 0 0.5
4 3 4 1 1 1 0.4 0.4 0 0.5 0.8 0 0.2 0.1 0 0.3 0.1 0.3 0.7 0.3 0.4 0
7 2 1 1 2 1 0.5 0.5 0.5 0 0 1 0 1.5 1.5 0.5 0.3 0.1 0 0.3 0.7 0.7
1 3 1 1 1 2 0 0.1 0.2 0.8 0.5 0.1 0.1 0 0.5 0.1 0.3 0.6 0.1 0 0 0.2
5 7 5 4 6 4 1 0.7 0.4 0.4 0.1 0.8 0.8 0 0.1 0.4 0 0.2 0.3 0 0 0.4
3 2 3 3 0.5 0.8 0.5 1 1 0.9 0.9 0.6 0.3 0 0.5 0.4
0 1 1 3 0.2 0 0.3 0.3 0 0.5 0.2 0.2 0 0.2 0.9 0.4
9 7 6 5 0.1 0.3 0.3 0.4 0.6 0.8 0.2 0.2 0.4 0.4 0 1
15 9 2 2 0 0.4 0.6 0.3 0.3 0 0 0.4 0.3
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ccd3 ccwk2 ccwk3 ccwk4 ccwk5 drrm drrl cld1m cld1l cld2m cld2l cld3m cld3l clwk2m clwk2l clwk3m clwk3l clwk4m clwk4l clwk5m clwk5l ciwd1m ciwd1l
0.2 0 0 1.48 1.83 1.25 1.8 1.39 1.89 1.28 1.83 1.08 1.63
0.3 0 0.5 0.2 0.1 2.56 2.85 2.73 3.11 3.25 2.82 2.67 3.07 3.04 2.93 2.93 3.92 3.92 2.85 3.2 5.17
0.3 0.1 0.3 2.3 4.77 1.74 2.09 2.12 4.5 1.74 4.22 2.15 4.15 6.92
0.1 0.4 0.2 0.3 0.1 3.57 2.99 3.02 2.35 2.91 2.76 3.63 3.25 3.28 2.73 3.34 2.99 3.46 3.11 3.28 3.08 4.42 3.81
0.1 0.4 0.2 0.5 0.2 2.73 2.11 2.48 1.66 2.83 1.91 2.95 2.09 2.23 1.4 2.78 2.04 2.26 1.49 4.59 3.7
0.4 0.4 0.8 0.2 0.5 2.54 2.12 2.51 2.01 2.88 2.2 2.35 1.73 2.54 2.33 1.88 2.65 1.96
0.1 0.2 0.2 1.37 1.45 1.02 1.05 1.48 1.48 1.25 1.31 1.02 1.02
0.5 0 0.1 0.1 0.1 2.16 1.88 1.85 2.1 1.4 1.71 1.84 1.76 1.99 1.92 2.12 1.63 1.97 1.58 1.75 5.01 5.1
0 0.4 0.1 0.2 0.7 2.3 2.27 2.48 1.93 2.17 2.56 2.09 2.17 1.69 2.17 1.66 1.91 1.51 4.98 4.44
0.3 0.8 0.1 3.51 2.87 2.73 2.07 2.97 2.31 3.08 2.47 2.32 1.73 2.65 2.15 4.79 4.04
0.1 0 0.2 2.31 1.69 2.31 1.53 1.99 1.5 2.55 1.93 2.31 1.69 1.78 1.43 4.6 3.54
0.8 0.6 0.3 3.03 2.74 2.02 3.26 2.98 3.01 2.73 2.88 2.55 3.11 2.86 4.17
0.8 0.6 0.4 2.34 2.22 2.08 1.86 1.96 1.73 1.93 1.77 1.7 4.72 4.39
0.3 0.3 0.3 2.62 2.14 2.05 1.99 2.11 2.04 2.36 2.24 2.19 2.11 2.21 2.16 4.12 3.88
0.8 0 0.3 0 0.4 3.2 2.91 3.25 3.25 3.1 2.65 2.92 2.18 2.27 3.11 3.37 2.71 2.35 2.59 5.72 5.7
0 0.5 0.2 2.49 2.65 2.79 2.65 2.71 2.68 2.55 2.76 2.15 1.78 1.91 5.18 5.52
0.1 0.2 0.6 2.65 1.7 2.7 1.45 2.58 1.43 2.43 1.35 2.58 1.35 4.98 3.59
0.3 0.3 0.3 2.44 2.71 2.39 2.76 1.98 1.82 2.03 2.01 1.93 1.94 5.05 4.89
0 0.3 0 2.06 1.89 1.51 1.26 2.53 2.23 2.21 2.09 1.97 1.97 4.74 4.39
0.3 0.5 0.3 0.2 0.1 2.88 2.26 2.18 3.05 2.38 2.28 2.78 2.18 5.54
0.5 0.1 0.6 0 0.5 2.96 2.3 2.22 2.54 1.81 2.34 1.58 2.58 1.68 2.73 2.02 4.82
0.1 0.6 0 0.4 0.1 1.95 1.9 2.02 1.88 2.29 2.13 2.13 1.68 1.61 1.2 1.79 1.68 3.51 3.35
0.5 0.7 0.1 0.1 0.6 1.7 1.6 1.65 1.43 1.79 1.9 1.54 1.56 1.01 1.9 1.43 1.7 1.6 2.09 1.38 4.24 4.02
0.1 0.4 0.3 2.67 2.43 2.7 2.74 2.73 2.74 2.62 2.47 2.88 2.93 2.93 3.2 5.38 5.6
1.2 0.3 0 1.46 1.32 2.44 2.25 1.84 2.05 1.22 1.75 1.79 1.75 8.76 9.22
0 0 0.3 2.24 2.24 2.18 2.12 2.41 2.21 1.89 2.15 2.18 2.09 1.92 1.74 4.39 4.59
0.3 0.1 0.1 1.48 1.69 1.77 1.6 1.92 1.39 2.18 1.74 2.15 1.45 1.98 7.67
ciwd2m ciwd2l ciwd3m ciwd3l ciwwk2m ciwwk2l ciwwk3m ciwwk3l ciwwk4m ciwwk4l ciwwk5m ciwwk5l cbd1m cbd1l cbd2m cbd2l
6.68 7.12 6.68 7.18 6.57 7.09 6.51 7.03 1.89 1.74
5.64 5.58 5.35 5.03 5.42 5.36 5.32 5.2 6.26 6.25 5.03 5.38 2.82 1.83 2.41
6.86 7.44 9.99 6.98 9.99 7.47 9.99 2.47 2.56
4.27 4.13 5.03 4.85 4.77 4.18 4.71 4.45 4.91 4.68 4.71 4.47 2.41 2.56 2.59 2.27
4.99 4.02 5.24 4.25 4.43 3.46 5.09 4.12 4.97 4.02 1.74 1.81 1.32 1.46
4.37 3.66 4.58 3.77 4.13 3.3 4.6 4.08 3.49 4.29 3.49 1.73 1.83
6.49 6.65 6.45 6.57 6.94 7.06 6.19 6.33 2.39 2.47
4.28 4.93 5.1 4.72 5.06 4.95 4.95 5.08 5.28 5.08 5.14 1.92 1.72 2.61 1.88
4.83 5.06 4.44 4.78 3.99 4.75 4.15 4.73 4.09 1.65 1.56 1.76
5.09 4.36 5.2 4.46 4.36 3.75 4.77 4.2 2.38 2.5 2.01 2.21
4.52 3.62 4.92 4.04 5.08 4.12 3.85 3.22 2.21 2.82 2.31 2.69
5.65 5.03 5.48 4.9 5.4 4.83 5.5 5 2.96 2.11 2.15
3.4 3.35 3.72 3.79 3.41 1.48 1.56 2.76 2.6
3.83 3.6 4.02 3.83 3.98 3.68 4.17 3.91 0.37 0.7 0.62 0.94
5.7 5.48 5.78 5.14 5.11 5.81 6.04 5.54 5.15 5.18 2.5 2.5 2.5
5.79 5.89 5.15 5.71 4.54 4.09 4.59 2.31 2.52 1.7 1.91
4.86 3.59 4.69 3.5 4.96 3.49 1.59 1.85 1.69 1.82
3.81 3.78 4.69 4.31 5.03 4.84 1.39 1.65 2.64 2.69
5.23 5.15 4.79 5.03 4.44 4.29 1.54 1.83 0.99 1.08
6.31 5.54 5.3 5.79 5.16 1.44
5.56 4.65 5.2 4.13 5.52 4.41 5.8 4.77 1.79
3.9 3.67 3.97 3.6 3.15 2.86 3.58 3.69 2.47 2.63
4.49 4.38 4.02 4.38 3.79 4.18 3.82 4.02 3.96 4.55 3.85 1.65 1.83 1.53
5.49 5.67 5.11 5.74 5.61 5.89 5.84 6.26 1.25 1.14 1.16 1.01
9.52 9.45 8.23 8.42 8.18 8.95 1.66 2.17
4.77 4.91 4.24 4.47 4.79 4.77 4.33 4.45 2.5 2.38 2.18 2.03
7.67 7.93 7.61 8.22 7.87 8.25 7.35 7.73 2.93 2.91 2.67
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cbd3m cbd3l cbwk2m cbwk2l cbwk3m cbwk3l cbwk4m cbwk4l cbwk5m cbwk5l
1.86 1.71 2.03 1.83 2.06 1.89
2.12 3.93 2.06 2.59 2.12 2.79 1.13 1.69 2.41 2.62
1.98 1.6 2.44 1.51 1.95 1.68
1.8 1.51 2.09 2.12 2.18 1.95 1.89 1.69 2.09 1.89
1.07 1.27 1.87 2.06 1.19 1.37 1.34 1.49
1.52 1.73 1.96 2.17 1.44 2.01 2.01 1.8 2.01
2.45 2.62 1.95 2.12 2.7 2.82
1.71 2.16 1.8 1.96 1.86 1.86 1.53 1.83 1.69
1.57 1.53 1.83 1.98 1.83 1.8 1.88 1.9
1.99 2.11 2.72 2.82 2.38 2.31
1.89 2.32 1.7 2.22 2.95 3.11
2.33 2.22 2.34 2.33 2.27 2.06
2.47 2.38 2.51
0.42 0.75 0.5 0.87 0.29 0.65
2.5 2.35 3.08 2.96 2.41 2.18 2.56 3.07 2.92
2.34 2.34 2.92 3.4 3.45
1.86 1.91 1.49 1.92
1.76 2.18 1.44 1.7
1.45 1.25 1.82 1.97
1.44 1.46 1.7 1.94 1.82
1.94 1.98 2.3 2.49 2 2.22 1.7 2
2.09 2.31 2.02 2.38 2.83 3.11 2.4 2.27
1.65 1.8 1.65 2.08 1.81 2 1.95 1.88 1.51 1.97
1.48 1.51 1.02 0.79 0.78 0.42
0.83 1.9 2.14 2.98 2.19 2.45
2.67 2.5 2.12 2.18 2.59 2.5
2.93 2.38 2.64 2.35 3.23 2.88
